<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Haloperidol versus placebo for schizophrenia - Adams, CE - 2013 | Cochrane Library</title> <meta content="Haloperidol versus placebo for schizophrenia - Adams, CE - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003082.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Haloperidol versus placebo for schizophrenia - Adams, CE - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003082.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003082.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Haloperidol versus placebo for schizophrenia" name="citation_title"/> <meta content="Clive E Adams" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="clive.adams@nottingham.ac.uk" name="citation_author_email"/> <meta content="Hanna Bergman" name="citation_author"/> <meta content="Enhance Reviews Ltd" name="citation_author_institution"/> <meta content="Claire B Irving" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Stephen Lawrie" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD003082.pub3" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/11/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003082.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003082.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003082.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Akathisia, Drug‐Induced [etiology]; Antipsychotic Agents [adverse effects, *therapeutic use]; Dystonia [chemically induced]; Haloperidol [adverse effects, *therapeutic use]; Parkinsonian Disorders [chemically induced]; Placebo Effect; Randomized Controlled Trials as Topic; Schizophrenia [*drug therapy]; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003082.pub3&amp;doi=10.1002/14651858.CD003082.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6iOnQIUh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003082\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003082\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003082.pub3",title:"Haloperidol versus placebo for schizophrenia",firstPublishedDate:"Nov 15, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6iOnQIUh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003082.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003082.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003082.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003082.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003082.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003082.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003082.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003082.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003082.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003082.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4324 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003082.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/full#CD003082-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/full#CD003082-sec-0175"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/full#CD003082-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/full#CD003082-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/full#CD003082-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/full#CD003082-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/full#CD003082-sec-0097"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/full#CD003082-sec-0157"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/appendices#CD003082-sec-0185"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/table_n/CD003082StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/table_n/CD003082StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Haloperidol versus placebo for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/information#CD003082-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Clive E Adams</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/information#CD003082-cr-0003">Hanna Bergman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/information#CD003082-cr-0004">Claire B Irving</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003082.pub3/information#CD003082-cr-0005">Stephen Lawrie</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/information/en#CD003082-sec-0192">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 November 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003082.pub3">https://doi.org/10.1002/14651858.CD003082.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003082-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003082-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003082-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003082-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003082-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003082-abs-0001" lang="en"> <section id="CD003082-sec-0001"> <h3 class="title" id="CD003082-sec-0001">Background</h3> <p>Haloperidol was developed in the late 1950s for use in the field of anaesthesia. Research subsequently demonstrated effects on hallucinations, delusions, aggressiveness, impulsiveness and states of excitement and led to the introduction of haloperidol as an antipsychotic. </p> </section> <section id="CD003082-sec-0002"> <h3 class="title" id="CD003082-sec-0002">Objectives</h3> <p>To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared with placebo. </p> </section> <section id="CD003082-sec-0003"> <h3 class="title" id="CD003082-sec-0003">Search methods</h3> <p>Initially, we electronically searched the databases of Biological Abstracts (1985‐1998), CINAHL (1982‐1998), <i>The Cochrane Library</i> (1998, Issue 4), The Cochrane Schizophrenia Group's Register (December 1998), EMBASE (1980‐1998), MEDLINE (1966‐1998), PsycLIT (1974‐1998), and SCISEARCH. We also checked references of all identified studies for further trial citations and contacted the authors of trials and pharmaceutical companies for further information and archive material. </p> <p>For the 2012 update, on 15 May 2012, we searched the Cochrane Schizophrenia Group’s Trials Register. </p> </section> <section id="CD003082-sec-0004"> <h3 class="title" id="CD003082-sec-0004">Selection criteria</h3> <p>We included all relevant randomised controlled trials comparing the use of haloperidol (any oral dose) with placebo for those with schizophrenia or other similar serious, non‐affective psychotic illnesses (however diagnosed). Our main outcomes of interest were death, loss to follow‐up, clinical and social response, relapse and severity of adverse effects. </p> </section> <section id="CD003082-sec-0005"> <h3 class="title" id="CD003082-sec-0005">Data collection and analysis</h3> <p>We evaluated data independently and extracted, re‐inspected and quality assessed the data. We analysed dichotomous data using risk ratio (RR) and calculated their 95% confidence intervals (CI). For continuous data, we calculated mean differences (MD). We excluded continuous data if loss to follow‐up was greater than 50% and inspected data for heterogeneity. We used a fixed‐effect model for all analyses. For the 2012 update, we assessed risk of bias of included studies and used the GRADE approach to create a 'Summary of findings' table. </p> </section> <section id="CD003082-sec-0006"> <h3 class="title" id="CD003082-sec-0006">Main results</h3> <p>Twenty‐five trials randomising 4651 people are now included in this review. We chose seven main outcomes of interest for the 'Summary of findings' table. More people allocated haloperidol improved in the first six weeks of treatment than those given placebo (4 RCTs n = 472, RR 0.67 CI 0.56 to 0.80, <i>moderate quality evidence</i> ). A further eight trials also found a difference favouring haloperidol across the six weeks to six months period (8 RCTs n = 307 RR 0.67 CI 0.58 to 0.78, <i>moderate quality evidence</i> ). Relapse data from two trials favoured haloperidol at &lt; 52 weeks but the evidence was <i>very low quality</i> (2 RCTs n = 70, RR 0.69 CI 0.55 to 0.86). <i>Moderate quality evidence</i> showed about half of those entering studies failed to complete the short trials (six weeks to six months), although, at up to six weeks, 16 studies found a difference that marginally favoured haloperidol (n = 1812, RR 0.87 CI 0.80 to 0.95). Adverse effect data does, nevertheless, support clinical impression that haloperidol is a potent cause of movement disorders, at least in the short term. <i>Moderate quality evidence</i> indicates that haloperidol caused parkinsonism (5 RCTs n = 485, RR 5.48 CI 2.68 to 11.22), akathisia (6 RCTs n = 695, RR 3.66 CI 2.24 to 5.97, and acute dystonia (5 RCTs n = 471, RR 11.49 CI 3.23 to 10.85). Discharge from hospital was equivocal between groups (1 RCT n = 33, RR 0.85 CI 0.47 to 1.52, <i>very low quality evidence</i>). Data were not reported for death and patient satisfaction. </p> </section> <section id="CD003082-sec-0007"> <h3 class="title" id="CD003082-sec-0007">Authors' conclusions</h3> <p>Haloperidol is a potent antipsychotic drug but has a high propensity to cause adverse effects. Where there is no treatment option, use of haloperidol to counter the damaging and potentially dangerous consequences of untreated schizophrenia is justified. However, where a choice of drug is available, people with schizophrenia and clinicians may wish to prescribe an alternative antipsychotic with less likelihood of adverse effects such as parkinsonism, akathisia and acute dystonias. Haloperidol should be less favoured as a control drug for randomised trials of new antipsychotics. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003082-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003082-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003082-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003082-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003082-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003082-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003082-abs-0005">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003082-abs-0004" lang="en"> <h3>Haloperidol versus placebo for schizophrenia</h3> <p>Haloperidol was first developed in the late 1950s. Research subsequently showed its therapeutic effects on the symptoms of schizophrenia, such as hearing voices and seeing things (hallucinations), having strange beliefs (delusions), aggressiveness, impulsiveness and states of excitement. This led to the introduction of haloperidol as one of the first antipsychotic drugs. Antipsychotic drugs are the main treatment for the symptoms of schizophrenia. Despite the introduction of newer antipsychotic drugs (second generation or ‘atypical’ drugs), haloperidol remains in widespread use and is the benchmark for judging the effectiveness of newer antipsychotic drugs. </p> <p>The aim of this review was to evaluate the effects of haloperidol for schizophrenia and other similar serious mental illnesses compared with ‘dummy’ or no treatment (placebo). A new search for trials was carried out in May 2012 and the review now includes 25 studies with a total of 4651 people. Review authors rated the quality of evidence reported in the trials for seven main outcomes (global state, death, discharge from hospital, relapse, leaving the study early, adverse effects and satisfaction with treatment). For global state, leaving the study early and adverse effects the reviewers rated the evidence as moderate quality, however, relapse and discharge from hospital were rated to be very low quality evidence. There were no data available for death and satisfaction with treatment. </p> <p>Based on moderate quality evidence, haloperidol was found to be better than placebo in treating schizophrenia. More people given haloperidol improved in the first six weeks of treatment than those given placebo. However, a significant number of people on haloperidol suffered from side effects, including muscle stiffness, uncontrollable shaking, tremors, sleepiness and restlessness. </p> <p>Authors concluded that haloperidol is a potent and effective antipsychotic for treating the symptoms of schizophrenia but has the potential to cause debilitating side effects. People with schizophrenia and psychiatrists may wish to prescribe a newer antipsychotic drug with fewer side effects. </p> <p>Finally, a large proportion of other information and data in the trials were poor and badly reported, meaning that better studies are required. Many people, from both groups left the trials early. This suggests that the design and running of the trials was poor and perhaps not acceptable to people. In light of these findings, it is perhaps surprising that haloperidol is a benchmark antipsychotic in widespread use for treating schizophrenia. It is also surprising that haloperidol is widely used as a comparison for new medication. Haloperidol is an effective antipsychotic drug but has serious and debilitating side effects. </p> <p>Benjamin Gray, Service User and Service User Expert, Rethink Mental Illness.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003082-sec-0175" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003082-sec-0175"></div> <h3 class="title" id="CD003082-sec-0176">Implications for practice</h3> <section id="CD003082-sec-0176"> <section id="CD003082-sec-0177"> <h5 class="title">1. For people with schizophrenia</h5> <p>Even with this limited data set it can be seen that haloperidol is a potent antipsychotic drug but has a high propensity to cause adverse effects. The addition of new data further strengthens this observation. Given the choice, people with schizophrenia may wish to switch to another antipsychotic with less likelihood of causing parkinsonism, akathisia and acute dystonias. </p> </section> <section id="CD003082-sec-0178"> <h5 class="title">2. For clinicians</h5> <p>Haloperidol remains a benchmark for modern treatments. This review supports and, perhaps for the first time, objectively quantifies evidence of clinical experience. Clinicians with little choice of treatment should be reassured that the evidence for haloperidol's antipsychotic effect is borne out by trials and that it should remain as one useful treatment option. Where several antipsychotics are available to a clinician, the comparative effects, including adverse effects of each antipsychotic, should be carefully considered. </p> </section> <section id="CD003082-sec-0179"> <h5 class="title">3. For managers and policy makers</h5> <p>Haloperidol is inexpensive and effective. Initial cost savings could be offset by the consequences of adverse effects, which may include poor compliance with medication. It is important that a person with schizophrenia is treated for their illness. Policy makers must take into account the evidence as presented in this review and formulate humane, culturally sensitive, policy optimising a persons' chance of maintaining recovery. </p> </section> </section> <h3 class="title" id="CD003082-sec-0180">Implications for research</h3> <section id="CD003082-sec-0180"> <section id="CD003082-sec-0181"> <h5 class="title">1. General</h5> <p>More well designed, conducted and reported randomised trials would probably have allowed this review to be more authoritative and comprehensive. Much data were lost due to poor reporting, even in some of the most recent studies. </p> </section> <section id="CD003082-sec-0182"> <h5 class="title">2. Specific</h5> <p>It is unfortunate to have to mention that there is still scope for better designed, conducted and reported randomised trials on the absolute effects of haloperidol after nearly five decades of research. Although such trials might be of academic interest, we recognise that new placebo‐controlled studies are unlikely. However, using haloperidol as the control drug in randomised controlled trials evaluating new antipsychotics is likely to continue to be common practice. Haloperidol is an effective antipsychotic. However, with such common, marked, and unacceptable adverse effects, any comparison with almost any other antipsychotic is going to suggest that the experimental compound has a more favourable adverse effect profile. Haloperidol should be less favoured as a control drug. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003082-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003082-sec-0022"></div> <div class="table" id="CD003082-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HALOPERIDOL versus PLACEBO for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HALOPERIDOL versus PLACEBO for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> hospital and community<br/> <b>Intervention:</b> HALOPERIDOL versus PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HALOPERIDOL versus PLACEBO</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death ‐ suicide and natural causes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall improvement: No marked global improvement</b> <br/> Rated by clinician<br/> Follow‐up: &gt;6‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>841 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>564 per 1000</b> <br/> (488 to 656) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.67</b> <br/> (0.58 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>307<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Another four trials reported on this outcome at up to six weeks follow‐up, and one trial at &gt; 6‐24 weeks follow‐up using a nurse‐rated scale, both sub‐analyses showed significant results in favour of haloperidol. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Not discharged from hospital</b> <br/> Follow‐up: &gt; 6‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>625 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>531 per 1000</b> <br/> (294 to 950) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> <br/> (0.47 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> <br/> Follow‐up: &lt; 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>690 per 1000</b> <br/> (550 to 860) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b> <br/> (0.55 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: &gt; 6‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>134 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> <br/> (39 to 134) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.54</b> <br/> (0.29 to 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Another 16 trials reported on this outcome at up to six weeks follow‐up showing a significant result in favour of haloperidol. One trial at &lt; 52 weeks follow‐up showed no difference between haloperidol and placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: Movement disorders ‐ parkinsonism</b> <br/> Follow‐up: 3 weeks to 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>154 per 1000</b> <br/> (75 to 315) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.48</b> <br/> (2.68 to 11.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Several studies also reported on other, specific movement disorders: there was a significant result favouring placebo for akathisia, dystonia, needing anti‐Parkinson medication, rigidity and tremor; there was no difference between haloperidol and placebo for tardive dyskinesia, oculogyric crises, teeth grinding and 'thick' speech. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Seven out of the eight included studies had an unclear risk of bias for random sequence generation and for allocation concealment. Blinding of participants and personnel was unclear in four studies and blinding of assessors was unclear in six. Two studies had an unclear risk of bias for incomplete outcome data. One study had a high risk of other bias as they were funded by industry and three an unclear risk of bias as the drugs were provided by a pharmaceutical company.<br/> <sup>2</sup> The included study had an unclear risk of bias for random sequence generation, allocation concealment, and blinding of outcome assessors.<br/> <sup>3</sup> The total number of participants and events were very low.<br/> <sup>4</sup> Only one out of the 25 included studies reported on this outcome.<br/> <sup>5</sup> The two included studies had an unclear risk of bias for random sequence generation, allocation concealment, and for blinding of outcome assessors. One study had a high risk of bias for incomplete outcome data, the other an unclear risk of bias.<br/> <sup>6</sup> Only two out of the 25 included studies reported on this outcome.<br/> <sup>7</sup> Four out of the five included studies had an unclear risk of bias for random sequence generation, and all five studies had an unclear risk of bias for allocation concealment. Blinding of participants and personnel was unclear in two studies and blinding of assessors was unclear in four. One study had a high risk of bias for incomplete outcome data, and two for other bias as they were funded by industry or the drugs were provided by a pharmaceutical company. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003082-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003082-sec-0023"></div> <section id="CD003082-sec-0024"> <h3 class="title" id="CD003082-sec-0024">Description of the condition</h3> <p>Schizophrenia affects about 1% of the world's population, irrespective of race, gender, social class or country of origin (<a href="./references#CD003082-bbs2-0161" title="JablenskyA , SartoriusN , ErnbergG , AnkerM , KortenA , CooperJE , et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten‐country study. Psychological Medicine Monograph Supplement1992;20:1‐97. ">Jablensky 1992</a>). Central to the treatment of this disabling mental illness are antipsychotic drugs, the earliest of which, chlorpromazine and haloperidol, were formulated and introduced in the 1950's. This introduction caused a revolution in the care of those with serious mental illnesses (<a href="./references#CD003082-bbs2-0138" title="AwadGA , VorugantiLNP , HeslegraveRJ . Measuring quality of life in patients with schizophrenia. PharmacoEconomics1997;11:32‐47. ">Awad 1997</a>; <a href="./references#CD003082-bbs2-0146" title="DallyP . Chemotherapy of Psychiatric Disorders. Logo Press Limited1967. ">Dally 1967</a>). Despite the formulation of a newer generation of atypical antipsychotics, chlorpromazine and haloperidol are still the most frequently prescribed antipsychotic drugs world‐wide (<a href="./references#CD003082-bbs2-0140" title="AydFJ . Haloperidol: twenty years' clinical experience. Journal of Clinical Psychiatry1978;39:807‐14. ">Ayd 1978</a>; <a href="./references#CD003082-bbs2-0145" title="CarpenterWT , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681‐90. ">Carpenter 1994</a>; <a href="./references#CD003082-bbs2-0175" title="WaddingtonJL , ScullyPJ , O'CallaghanE . The new antipsychotics, and their potential for early intervention in schizophrenia. Schizophrenia Research1997;28:207‐22. ">Waddington 1997</a>). </p> </section> <section id="CD003082-sec-0025"> <h3 class="title" id="CD003082-sec-0025">Description of the intervention</h3> <p>Haloperidol was developed in the late 1950s for use in the field of anaesthesia and was initially used to prevent surgical shock. Research subsequently demonstrated its beneficial effect on hallucinations, delusions, aggressiveness, impulsiveness and states of excitement (<a href="./references#CD003082-bbs2-0139" title="AydFJ . Haloperidol: fifteen years of clinical experience. Diseases of the Nervous System1972;33:459‐69. ">Ayd 1972</a>; <a href="./references#CD003082-bbs2-0140" title="AydFJ . Haloperidol: twenty years' clinical experience. Journal of Clinical Psychiatry1978;39:807‐14. ">Ayd 1978</a>; <a href="./references#CD003082-bbs2-0171" title="SettleEC , AydFJ . Haloperidol: a quarter century of experience. Journal of Clinical Psychiatry1983;44:440‐8. ">Settle 1983</a>). These findings led to the introduction of haloperidol as an antipsychotic. Hailed as a breakthrough, it was considered to be the most potent antipsychotic known, effective for a wide range of psychotic disorders, and in addition, appeared to keep side effects to a minimum (<a href="./references#CD003082-bbs2-0171" title="SettleEC , AydFJ . Haloperidol: a quarter century of experience. Journal of Clinical Psychiatry1983;44:440‐8. ">Settle 1983</a>). Since its introduction, clinical experience has suggested that haloperidol is indeed an effective antipsychotic, particularly beneficial for those who are experiencing acute hallucinations and delusions. </p> </section> <section id="CD003082-sec-0026"> <h3 class="title" id="CD003082-sec-0026">How the intervention might work</h3> <p>Antipsychotic drugs block, to a greater or lesser extent, the transmission of dopamine, which is implicated in the cause of schizophrenia, in the brain (<a href="./references#CD003082-bbs2-0176" title="WillnerP . The dopamine hypothesis of schizophrenia: Current status, future prospects. International Clinical Psychopharmacology1997;12:297‐308. ">Willner 1997</a>). The action of these drugs is not specific and unwanted blockade can occur. This produces a wide range of side effects including lethargy, sedation, dry mouth, blurred vision, constipation, weight gain, and stiffness. Haloperidol has a higher potency dopamine blockade compared to most other antipsychotics, therefore, low‐dose haloperidol can be used to achieve an antipsychotic effect. This keeps the sort of adverse effects described above to a minimum. Haloperidol's high potency for dopamine blockade, however, means that it may cause more disorders of movement and expression (parkinsonism), involuntary and perhaps irreversible movements (dyskinesia), overwhelming feelings of restlessness (akathisia) and dangerous disturbances of the body's temperature and blood pressure regulatory systems (neuroleptic malignant syndrome) (<a href="./references#CD003082-bbs2-0171" title="SettleEC , AydFJ . Haloperidol: a quarter century of experience. Journal of Clinical Psychiatry1983;44:440‐8. ">Settle 1983</a>). </p> <p>Despite these recent concerns, research in general has consistently found haloperidol to be an effective, well tolerated antipsychotic that produces minimal side effects (<a href="./references#CD003082-bbs2-0139" title="AydFJ . Haloperidol: fifteen years of clinical experience. Diseases of the Nervous System1972;33:459‐69. ">Ayd 1972</a>; <a href="./references#CD003082-bbs2-0140" title="AydFJ . Haloperidol: twenty years' clinical experience. Journal of Clinical Psychiatry1978;39:807‐14. ">Ayd 1978</a>; <a href="./references#CD003082-bbs2-0171" title="SettleEC , AydFJ . Haloperidol: a quarter century of experience. Journal of Clinical Psychiatry1983;44:440‐8. ">Settle 1983</a>). Consequently, in accordance with the recommendations of drug regulatory authorities, such as the Food and Drug Administration (FDA) of the United States of America, haloperidol is increasingly used as a comparator drug in clinical trials (<a href="./references#CD003082-bbs2-0171" title="SettleEC , AydFJ . Haloperidol: a quarter century of experience. Journal of Clinical Psychiatry1983;44:440‐8. ">Settle 1983</a>; <a href="./references#CD003082-bbs2-0173" title="ThornleyB , AdamsC . Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ1998;317:1181‐4. ">Thornley 1998</a>). To an even greater extent than chlorpromazine, haloperidol remains the benchmark by which all other antipsychotics are measured. </p> </section> <section id="CD003082-sec-0027"> <h3 class="title" id="CD003082-sec-0027">Why it is important to do this review</h3> <p>Haloperidol's efficacy as an antipsychotic seems to vary. Some research suggests factors such as drug dose, administration of antiparkinson medication, recipient's age, sex, and individual physiology may all change efficacies (<a href="./references#CD003082-bbs2-0139" title="AydFJ . Haloperidol: fifteen years of clinical experience. Diseases of the Nervous System1972;33:459‐69. ">Ayd 1972</a>; <a href="./references#CD003082-bbs2-0140" title="AydFJ . Haloperidol: twenty years' clinical experience. Journal of Clinical Psychiatry1978;39:807‐14. ">Ayd 1978</a>; <a href="./references#CD003082-bbs2-0171" title="SettleEC , AydFJ . Haloperidol: a quarter century of experience. Journal of Clinical Psychiatry1983;44:440‐8. ">Settle 1983</a>). More recently there has been increasing concern and debate surrounding the long‐term use of haloperidol and the subsequent development of serious adverse side effects (<a href="./references#CD003082-bbs2-0171" title="SettleEC , AydFJ . Haloperidol: a quarter century of experience. Journal of Clinical Psychiatry1983;44:440‐8. ">Settle 1983</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003082-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003082-sec-0028"></div> <p>To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared with placebo. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003082-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003082-sec-0029"></div> <section id="CD003082-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003082-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included all relevant randomised controlled trials. We included trials that implied randomisation, i.e. the trial was described as 'double‐blind' and the participants' demographic details in each group were similar. We excluded quasi‐randomised studies, such as those allocating by using alternate days of the week. </p> </section> <section id="CD003082-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included anyone with schizophrenia or similar serious, non‐affective psychosis diagnosed by any criteria, irrespective of gender, age or race. We accepted a trial including people with less serious mental illnesses if the majority of participants suffered from serious functional psychotic illnesses, such as schizophrenia. </p> </section> <section id="CD003082-sec-0033"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD003082-list-0001"> <li> <p>Haloperidol: any oral dose.*</p> </li> <li> <p>Placebo: active or inactive.</p> </li> </ol> </p> <p>* Depot administration of haloperidol has been evaluated in another Cochrane Review (<a href="./references#CD003082-bbs2-0169" title="QuraishiS , DavidA . Depot haloperidol decanoate for schizophrenia. Cochrane Database of Systematic Reviews1999, Issue 1. [DOI: 10.1002/14651858.CD001361] ">Quraishi 1999</a>), and if trials relevant to this comparison were found we sent these to the contact author of this review. A systematic review of haloperidol, one dose versus another, has also been published (<a href="./references#CD003082-bbs2-0150" title="DonnellyL , RathboneJ , AdamsCE . Haloperidol dose for the acute phase of schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD001951.pub2] ">Donnelly 2013</a>) and relevant studies were also supplied to this review author. </p> </section> <section id="CD003082-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>We also grouped outcomes into immediate (up to six weeks), short (six weeks to six months), medium (six months to one year), and long (over one year) term. </p> <section id="CD003082-sec-0035"> <h5 class="title">Primary outcomes</h5> <section id="CD003082-sec-0036"> <h6 class="title">1. Death ‐ suicide and natural causes</h6> </section> <section id="CD003082-sec-0037"> <h6 class="title">2. Global state</h6> <p>2.1 Overall improvement<br/> 2.2 Relapse ‐ as defined by each study<br/> 2.3 Hospital discharge </p> </section> <section id="CD003082-sec-0038"> <h6 class="title">3. Satisfaction with treatment</h6> </section> <section id="CD003082-sec-0039"> <h6 class="title">4. Behaviour</h6> <p>4.1 Specific behaviours (e.g. aggressive or violent behaviour)</p> </section> </section> <section id="CD003082-sec-0040"> <h5 class="title">Secondary outcomes</h5> <section id="CD003082-sec-0041"> <h6 class="title">1. Global state</h6> <p>1.1 Duration of hospital stay<br/> 1.2 Re‐admission<br/> 1.3 Leaving the study early </p> </section> <section id="CD003082-sec-0042"> <h6 class="title">2. Mental state</h6> <p>2.1 General symptoms<br/> 2.2 Specific symptoms<br/> 2.2.1 Positive symptoms (delusions, hallucinations, disordered thinking)<br/> 2.2.2 Negative symptoms (avolition, poor self‐care, blunted affect)<br/> 2.2.3 Mood ‐ depression </p> </section> <section id="CD003082-sec-0043"> <h6 class="title">3. Behaviour</h6> <p>3.1 General behaviour<br/> 3.2.1 Social functioning<br/> 3.2.2 Employment status during trial (employed/unemployed)<br/> 3.2.3 Occurrence of violent incidents (to self, others or property) </p> </section> <section id="CD003082-sec-0044"> <h6 class="title">4. Adverse effects</h6> <p>4.1 General<br/> 4.2 Specific<br/> 4.2.1 Movement disorders<br/> 4.2.2 Other CNS<br/> 4.2.3 Cardiovascular effects<br/> 4.2.4 Others </p> </section> <section id="CD003082-sec-0045"> <h6 class="title">5. Economic</h6> <p>5.1 Cost of care</p> </section> <section id="CD003082-sec-0046"> <h6 class="title">6. ,Summary of findings, table</h6> <p>We used the <a href="http://www.ims.cochrane.org/revman/gradepro" target="_blank">GRADE</a> approach to interpret findings (<a href="./references#CD003082-bbs2-0170" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>) and used the GRADE profiler to import data from Review Manager (<a href="http://www.ims.cochrane.org/revman" target="_blank">RevMan</a>) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient‐care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table. </p> <p> <ol id="CD003082-list-0002"> <li> <p>Death ‐ suicide and natural causes.</p> </li> <li> <p>Overall improvement.</p> </li> <li> <p>Not discharged from hospital.</p> </li> <li> <p>Relapse.</p> </li> <li> <p>Leaving the study early</p> </li> <li> <p>Satisfaction with treatment ‐ participant/carer.</p> </li> <li> <p>Adverse effects: Movement disorders ‐ parkinsonism.</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD003082-sec-0047"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003082-sec-0048"> <h4 class="title">Electronic searches</h4> <p>For details of the search terms and previous searches see <a href="./appendices#CD003082-sec-0186">Appendix 1</a> </p> <section id="CD003082-sec-0049"> <h5 class="title">Cochrane Schizophrenia Group Trials Register (May 2012)</h5> <p>The Trials Search Co‐ordinator searched the Cochrane Schizophrenia Group’s Trials Register (15 May 2012).<br/> The Cochrane Schizophrenia Group’s Trials Register is compiled by systematic searches of major databases, handsearches and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">group module</a>). </p> </section> </section> <section id="CD003082-sec-0050"> <h4 class="title">Searching other resources</h4> <section id="CD003082-sec-0051"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of all identified studies for further relevant studies.</p> </section> <section id="CD003082-sec-0052"> <h5 class="title">2. Personal contact</h5> <p>For this update, we did not contact the first author of each included study for information regarding unpublished trials. </p> </section> </section> </section> <section id="CD003082-sec-0053"> <h3 class="title" id="CD003082-sec-0053">Data collection and analysis</h3> <p>Methods used in data collection and analysis for this 2012 update are set out below; for previous methods, please see <a href="./appendices#CD003082-sec-0187">Appendix 2</a>. </p> <section id="CD003082-sec-0054"> <h4 class="title">Selection of studies</h4> <p>For this 2012 update, the Cochrane Schizophrenia group provided Enhance Reviews, a database of relevant abstracts; the Enhance Reviews team inspected full articles of the abstracts meeting the inclusion criteria. </p> </section> <section id="CD003082-sec-0055"> <h4 class="title">Data extraction and management</h4> <section id="CD003082-sec-0056"> <h5 class="title">1. Extraction</h5> <p>For this 2012 update, two members of the Enhance Reviews team extracted data from included studies. We extracted data presented only in graphs and figures whenever possible. In the previous versions of the review, when further information was necessary, we contacted authors of studies in order to obtain missing data, or for clarification. If studies were multi‐centre, where possible, we extracted data relevant to each component centre separately. </p> </section> <section id="CD003082-sec-0057"> <h5 class="title">2. Management</h5> <section id="CD003082-sec-0058"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, simple forms, created in a web‐based software (<a href="./references#CD003082-bbs2-0148" title="DistillerSR. www.systematic‐review.net. ">DistillerSR</a>). </p> </section> <section id="CD003082-sec-0059"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> a) the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD003082-bbs2-0167" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b) the measuring instrument has not been written or modified by one of the trialists for that particular trial. </p> <p>Ideally, the measuring instrument should either be i. a self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we have noted whether or not this is the case in <a href="#CD003082-sec-0098">Description of studies</a>. </p> </section> <section id="CD003082-sec-0060"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised mean differences throughout (<a href="./references#CD003082-bbs2-0160" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>, Chapter 9.4.5.2). </p> </section> <section id="CD003082-sec-0061"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we aimed to apply the following standards to all data before inclusion: </p> <p>a) standard deviations (SDs) and means are reported in the paper or obtainable from the authors; </p> <p>b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<a href="./references#CD003082-bbs2-0137" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313:1200. ">Altman 1996</a>)); </p> <p>c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS) (<a href="./references#CD003082-bbs2-0162" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S‐S min), where S is the mean score and S min is the minimum score. </p> <p>Endpoint scores on scales often have a finite start and end point and these rules can be applied. We entered skewed endpoint data from studies of fewer than 200 participants in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at mean if the sample size is large; we entered such endpoint data into syntheses. </p> <p>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not, we entered skewed change data into analyses regardless of the size of the study. </p> </section> <section id="CD003082-sec-0062"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD003082-sec-0063"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD003082-bbs2-0168" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the PANSS (<a href="./references#CD003082-bbs2-0162" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD003082-bbs2-0164" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005</a>; <a href="./references#CD003082-bbs2-0165" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005a</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD003082-sec-0064"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for haloperidol. </p> </section> </section> </section> <section id="CD003082-sec-0065"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For this 2012 update, two members of the Enhance Reviews team worked independently by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003082-bbs2-0160" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) to assess trial quality for the new included studies and all previously included studies. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>Where inadequate details of randomisation and other characteristics of trials were provided, we did not contact authors of the studies in order to obtain additional information. </p> <p>We have noted the level of risk of bias in both the text of the review and in the <a href="./full#CD003082-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD003082-sec-0066"> <h4 class="title">Measures of treatment effect</h4> <section id="CD003082-sec-0067"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD003082-bbs2-0144" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD003082-bbs2-0147" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). </p> </section> <section id="CD003082-sec-0068"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes we estimated mean difference (MD) between groups. We would prefer not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity had been used, we would have presumed there was a small difference in measurement, and we would have calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD003082-sec-0069"> <h4 class="title">Unit of analysis issues</h4> <section id="CD003082-sec-0070"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD003082-bbs2-0149" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>) whereby P values are spuriously low, confidence intervals (CIs) unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD003082-bbs2-0143" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD003082-bbs2-0156" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>If we had included cluster trials and if clustering had not been accounted for in the primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, if we include cluster trials, we will seek to contact the first authors of studies to obtain intra‐class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD003082-bbs2-0156" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). Where clustering has been incorporated into the analysis of primary studies, we will present these data as if from a non‐cluster randomised study, but adjust for the clustering effect. </p> <p>For adjustment for clustering a posteriori, the binary data as presented in a report are divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m‐1)*ICC] (<a href="./references#CD003082-bbs2-0151" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC is not reported, it will be assumed to be 0.1 (<a href="./references#CD003082-bbs2-0174" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organistation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). </p> <p>If cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies will be possible using the generic inverse variance technique. </p> </section> <section id="CD003082-sec-0071"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD003082-bbs2-0153" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we only used data of the first phase of cross‐over studies. </p> </section> <section id="CD003082-sec-0072"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involves more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary, we simply added these and combined within the two‐by‐two table. If data were continuous, we combined data following the formula in section 7.7.3.8 (Combining groups) of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD003082-bbs2-0160" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). Where the additional treatment arms were not relevant, we did not reproduce these data. </p> </section> </section> <section id="CD003082-sec-0073"> <h4 class="title">Dealing with missing data</h4> <section id="CD003082-sec-0074"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD003082-bbs2-0177" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses, with the exception of the outcome leaving the study early. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we addressed this within the 'Summary of findings' table/s by down‐rating quality. Finally, we also downgraded quality within the 'Summary of findings' table/s should loss be 25% to 50% in total. </p> </section> <section id="CD003082-sec-0075"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat analysis). Those leaving the study early were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes, the rate of those who stayed in the study ‐ in that particular arm of the trial ‐ were used for those who did not. We undertook a sensitivity analysis to test how prone the primary outcomes were to change when 'completer' data only were, compared to the intention‐to‐treat analysis using the above assumptions. </p> </section> <section id="CD003082-sec-0076"> <h5 class="title">3. Continuous</h5> <section id="CD003082-sec-0077"> <h6 class="title">3.1 Attrition</h6> <p>In the case where attrition for a continuous outcome was between 0% and 50% and completer‐only data were reported, we reproduced these. </p> </section> <section id="CD003082-sec-0078"> <h6 class="title">3.2 Standard deviations</h6> <p>If standard deviations (SDs) were not reported, we first tried to obtain the missing values from the authors. If not available, where there are missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals (CIs) available for group means, and either a P value or T value available for differences in mean, we can calculate them according to the rules described in the <i>Cochrane Handbook</i> (<a href="./references#CD003082-bbs2-0160" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>): When only the SE is reported, SDs are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook</i> (<a href="./references#CD003082-bbs2-0160" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) present detailed formulae for estimating SDs from P values, T or F values, CIs, ranges or other statistics. If these formulae do not apply, we can calculate the SDs according to a validated imputation method which is based on the SDs of the other included studies (<a href="./references#CD003082-bbs2-0154" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> <section id="CD003082-sec-0079"> <h6 class="title">3.3 Last observation carried forward</h6> <p>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD003082-bbs2-0166" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>). Therefore, where LOCF data have been used in the trial, if less than 50% of the data have been assumed, we reproduced these data and indicated that they are the product of LOCF assumptions. </p> </section> </section> </section> <section id="CD003082-sec-0080"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD003082-sec-0081"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, we fully discussed these. </p> </section> <section id="CD003082-sec-0082"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, we fully discussed these. </p> </section> <section id="CD003082-sec-0083"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD003082-sec-0084"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD003082-sec-0085"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>We investigated heterogeneity between studies by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> P value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD003082-bbs2-0158" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. a P value from Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>). An I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant Chi<sup>2</sup> statistic was interpreted as evidence of substantial levels of heterogeneity (<a href="./references#CD003082-bbs2-0160" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (<a href="#CD003082-sec-0088">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD003082-sec-0086"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD003082-bbs2-0152" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). These are described in Section 10 of the <i>Cochrane Handbook</i> (<a href="./references#CD003082-bbs2-0160" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation. </p> </section> <section id="CD003082-sec-0087"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model: it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose the fixed‐effect model for all analyses. The reader is, however, able to choose to inspect the data using the random‐effects model. </p> </section> <section id="CD003082-sec-0088"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD003082-sec-0089"> <h5 class="title">1. Subgroup analyses ‐ only primary outcomes</h5> <section id="CD003082-sec-0090"> <h6 class="title">1.1 Clinical state, stage or problem</h6> <p>We proposed to undertake this review to provide an overview of the effects of haloperidol for people with schizophrenia in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems. </p> <p>We also undertook subgroup analyses comparing the results for the following:</p> <p> <ul id="CD003082-list-0003"> <li> <p>male versus female participants;</p> </li> <li> <p>under 18 years of age versus 18‐65 years old, versus older than 65 years;</p> </li> <li> <p>acute versus chronic phase of illness;</p> </li> <li> <p>low dose (≤ 5 mg/day) versus medium to high dose (&gt; 5 mg/day), or as defined by each study; </p> </li> <li> <p>use of anti‐Parkinson medication versus no use of anti‐Parkinson medication;</p> </li> <li> <p>people diagnosed according to any operational criteria versus those who have not been diagnosed using operational criteria. </p> </li> </ul> </p> </section> </section> <section id="CD003082-sec-0091"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency was high, we have reported this. First, we investigated whether data had been entered correctly. Second, if data were correct, we visually inspected the graph and successively removed outlying studies to see if homogeneity was restored. </p> <p>When unanticipated clinical or methodological heterogeneity was obvious, we simply stated hypotheses regarding these for future reviews or versions of this review. We did not undertake analyses relating to these. </p> </section> </section> <section id="CD003082-sec-0092"> <h4 class="title">Sensitivity analysis</h4> <p>We applied all sensitivity analyses to the primary outcomes of this review.</p> <section id="CD003082-sec-0093"> <h5 class="title">1. Implication of randomisation</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in some way so as to imply randomisation. For the primary outcomes, we included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we entered all data from these studies. </p> </section> <section id="CD003082-sec-0094"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD003082-sec-0073">Dealing with missing data</a>), we compared the findings of the primary outcomes when we use our assumption/s and when we used data only from people who completed the study to that point. A sensitivity analysis was undertaken to test how prone results were to change when completer‐only data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported results and discussed them, but continued to employ our assumption. </p> </section> <section id="CD003082-sec-0095"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available): allocation concealment, blinding and outcome reporting for the meta‐analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included data from these trials in the analysis. </p> </section> <section id="CD003082-sec-0096"> <h5 class="title">4. Imputed values</h5> <p>Had we included any cluster‐randomised trials, we would have undertaken a sensitivity analysis to assess the effects of including data from trials where imputed values were used for ICC in calculating the design effect in cluster‐randomised trials. </p> <p>If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003082-sec-0097" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003082-sec-0097"></div> <section id="CD003082-sec-0098"> <h3 class="title">Description of studies</h3> <p>Please see <a href="./references#CD003082-sec-0198" title="">Characteristics of included studies</a> and <a href="./references#CD003082-sec-0199" title="">Characteristics of excluded studies</a>. </p> <section id="CD003082-sec-0099"> <h4 class="title">Results of the search</h4> <p>From the 2012 search, we added five new trials (<a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a>; <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a>; <a href="./references#CD003082-bbs2-0016" title="MeltzerHY . Testing multiple novel mechanisms for treating schizophrenia in a single trial. In: CummingsJL editor(s). Progress in Neurotherapeutics and Neuropsychopharmacology. New York, NY, US: Cambridge University Press, 2006:115‐20. Meltzer , HY , ArvanitisL , BauerD , Rein W and Meta‐trial Study Group. Placebo‐controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. American Journal of Psychiatry2004;161(6):975‐84. ">Meltzer 2004</a>; <a href="./references#CD003082-bbs2-0017" title="NCT00044044 . A 6‐week, double‐blind, randomized, fixed‐dose, parallel‐group study of the efficacy and safety of three dose levels of SM‐13496 compared to placebo and haloperidol in patients with schizophrenia who are experiencing an acute exacerbation of symptoms. www.ClinicalTrials.gov (accessed on 30 Oct 2012).2002. ">NCT00044044 2002</a>; <a href="./references#CD003082-bbs2-0020" title="PotkinSG , LitmanRE , TorresR , WolfgangCD . Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. Journal of Clinical Psychopharmacology2008;28(2 Suppl 1):S4‐S11. ">Potkin 2008</a>) to the included studies, taking the total number of included studies to 25. Previous searches in 2005 and 1998 produced 2161 references; in addition to our own search, Dr Jo Wood, at Janseen‐Cilag UK Limited, kindly carried out a search of an in‐house databases and provided a further 104 possible references. A total of 2250 references have now been screened and 134 full texts retrieved for further inspection (See <a href="#CD003082-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD003082-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003082-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003082-sec-0100"> <h4 class="title">Included studies</h4> <section id="CD003082-sec-0101"> <h5 class="title">1. Methods</h5> <p>Most included studies had a parallel design, and four studies were cross‐over trials (<a href="./references#CD003082-bbs2-0010" title="HowardJ . Haloperidol for chronically hospitalised psychotics: A double‐blind comparison with thiothixene and placebo; a follow‐up open evaluation. Diseases of the Nervous System1974;35:458‐63. ">Howard 1974</a>; <a href="./references#CD003082-bbs2-0018" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics. Psychopharmacology1982;77:301‐4. ">Nishikawa 1982</a>; <a href="./references#CD003082-bbs2-0024" title="SpencerE , AlpertM , PougetE . Scales for the assessment of neuroleptic response in schizophrenic children: Specific measures derived from the CPRS. Psychopharmacology Bulletin1994;30:199‐202. SpencerEK , AlpertM , PougetER . [Two sensitive and specific scales derived from the CPRS for assessing haloperidol response in hospitalised schizophrenic children]. Proceedings of 33rd Annual Meeting of the New Clinical Drug Evaluation Unit. June 1‐4th; Boca Raton, USA. 1993. SpencerEK , KafantarisV , Padron‐GayolMV , RosenbergCR , CampbellM . Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacology Bulletin1992;28:183‐6. ">Spencer 1992</a>; <a href="./references#CD003082-bbs2-0025" title="VichaiyaV . Clinical trial of haloperidol in schizophrenia. Journal of Psychiatric Association of Thailand1971;16(1):31‐43. ">Vichaiya 1971</a>). All studies were either stated or described as being randomised. </p> </section> <section id="CD003082-sec-0102"> <h5 class="title">2. Length of trials</h5> <p>Schizophrenia is often chronic, and, in some cases, lifelong. This review categorised data into 'immediate' (up to six weeks), 'short‐term' (six weeks to six months), 'medium‐term' (six months to one year) and 'long ‐term' (over one year) follow‐up. Not one of the studies presented usable data on 'long‐term' follow‐up, only two (<a href="./references#CD003082-bbs2-0018" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics. Psychopharmacology1982;77:301‐4. ">Nishikawa 1982</a>; <a href="./references#CD003082-bbs2-0019" title="NishikawaT , TsudaA , TanakaM , HoakiY , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics: A comparative dose‐response study of haloperidol and propericiazine. Psychopharmacology1984;82:153‐6. ">Nishikawa 1984</a>) had a follow‐up of one year. Eight studies lasted for less than six weeks and the other 15 studies presented data that fell into the 'short‐term' category. A placebo wash‐out or a medication‐free period preceded treatment in all but six trials. </p> </section> <section id="CD003082-sec-0103"> <h5 class="title">3. Participants</h5> <p>Fifteen studies included people with schizophrenia diagnosed by DSM‐III, DSM‐III‐R or DSM‐IV criteria. The other 10 studies included people with schizophrenia, but did not describe the means of diagnosis. <a href="./references#CD003082-bbs2-0018" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics. Psychopharmacology1982;77:301‐4. ">Nishikawa 1982</a> and <a href="./references#CD003082-bbs2-0019" title="NishikawaT , TsudaA , TanakaM , HoakiY , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics: A comparative dose‐response study of haloperidol and propericiazine. Psychopharmacology1984;82:153‐6. ">Nishikawa 1984</a> included people who were stable and in remission. Other studies also included a few people with other mental illnesses such as neurosis (<a href="./references#CD003082-bbs2-0007" title="DurostH , LeeH , ArthursD . An early evaluation of Haloperidol. The Butyrophenones in Psychiatry. Edited by HE Lehmann and TA Ban. Channel Press Inc, 1964:70‐3. ">Durost 1964</a>) and major depressive disorder (<a href="./references#CD003082-bbs2-0014" title="KlieserE , LehmannE . Experimental examination of trazodone. Clinical Neuropharmacology1989;12:S18‐24. ">Klieser 1989</a>), in addition to people with schizophrenia. In these studies, only data for those suffering from schizophrenia were used. The majority of participants were hospitalised and chronically ill. Eight studies specifically stated that participants were currently acutely ill. Only one study included people who were under 18 years old (<a href="./references#CD003082-bbs2-0024" title="SpencerE , AlpertM , PougetE . Scales for the assessment of neuroleptic response in schizophrenic children: Specific measures derived from the CPRS. Psychopharmacology Bulletin1994;30:199‐202. SpencerEK , AlpertM , PougetER . [Two sensitive and specific scales derived from the CPRS for assessing haloperidol response in hospitalised schizophrenic children]. Proceedings of 33rd Annual Meeting of the New Clinical Drug Evaluation Unit. June 1‐4th; Boca Raton, USA. 1993. SpencerEK , KafantarisV , Padron‐GayolMV , RosenbergCR , CampbellM . Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacology Bulletin1992;28:183‐6. ">Spencer 1992</a>) and none included people who were over 65 years of age. Most trials were of mixed sex. <a href="./references#CD003082-bbs2-0010" title="HowardJ . Haloperidol for chronically hospitalised psychotics: A double‐blind comparison with thiothixene and placebo; a follow‐up open evaluation. Diseases of the Nervous System1974;35:458‐63. ">Howard 1974</a> and <a href="./references#CD003082-bbs2-0025" title="VichaiyaV . Clinical trial of haloperidol in schizophrenia. Journal of Psychiatric Association of Thailand1971;16(1):31‐43. ">Vichaiya 1971</a> included only women, while <a href="./references#CD003082-bbs2-0023" title="SimpsonGM , AngusJWS , EdwardsJG . A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research1967;9:407‐12. ">Simpson 1967</a> and <a href="./references#CD003082-bbs2-0003" title="BechelliLPC , Ruffino‐NettoA , HetemG . A double‐blind controlled trial of pipotiazine, haloperidol and placebo in recently hospitalised acute schizophrenic patients. Brazilian Journal of Biological Research1983;16:305‐11. ">Bechelli 1983</a> included only men. Only <a href="./references#CD003082-bbs2-0004" title="BorisonRL , SinahD , HaverstockS , McLarnonMC , DiamondB . Efficacy and safety of tiospirone vs haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989;25:190‐3. ">Borison 1989</a> did not describe the sex of participants. </p> </section> <section id="CD003082-sec-0104"> <h5 class="title">4. Setting</h5> <p>Trials mainly took place in inpatient settings. Two trials were conducted in outpatient settings (<a href="./references#CD003082-bbs2-0018" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics. Psychopharmacology1982;77:301‐4. ">Nishikawa 1982</a> and <a href="./references#CD003082-bbs2-0019" title="NishikawaT , TsudaA , TanakaM , HoakiY , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics: A comparative dose‐response study of haloperidol and propericiazine. Psychopharmacology1984;82:153‐6. ">Nishikawa 1984</a>), and three in a mixture of inpatient and outpatient settings (<a href="./references#CD003082-bbs2-0002" title="Ascher‐SvanumH , StenslandMD , KinonBJ , TollefsonGD . Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. Journal of Psychopharmacology2005;19(6 Suppl):110‐7. [MEDLINE: 16280344] BeasleyC , TollefsonGD , BeuzenJN , DellvaMA , SangerTM , PaulS . Acute and long‐term results of the North American double‐blind olanzapine trial. Proceedings of the 4th International Conference. October 6‐9th; Vancouver BC, Canada. 1996. BeasleyCM , TollefsonG , TranP , SatterleeW , SangerT , HamiltonS , Olanzapine HGAD study group. Olanzapine versus placebo and haloperidol; Acute phase results of the North American double‐blind olanzapine trial. Neuropsychopharmacology1996;14:111‐23. BeasleyCM , TollefsonGD , TranPV . Efficacy of Olanzapine: An overview of pivotal clinical trials. Journal of Clinical Psychiatry1997;58:7‐12. CrawfordAMK , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research1997;26:41‐54. HamiltonSH , RevickiDA , GendusoLA , BeasleyCM . Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double‐blind trial. Neuropsychopharmacology1998;18:41‐9. PerryPJ , LundBC , SangerT , BeasleyC . Olanzapine plasma concentrations and clinical response: Acute phase results of the North American Olanzapine trial. Journal of Clinical Psychopharmacology2001;21:14‐20. RevickiD , GendusoL . Effect of Olanzapine on deficit syndrome symptoms in chronic schizophrenia. Proceedings of 8th ECNP (European College of Neuropsychopharmacology) Congress; September 30th ‐ October 4th; Venice, Italy. 1997. SangerT , TollefsonGD . A controlled study on the course of primary and secondary negative symptoms. Proceedings of 150th American Psychiatric Association Annual Meeting. San Diego, USA. 1997. SatterleeW , BeasleyC , SangerT , TranP , TollefsonG . Olanzapine, a new atypical antipsychotic. Proceedings of 5th International Congress on Schizophrenia Research. April 6‐12th; Wormsprings, USA. 1996. TollefsonG . Update on new atypical antipsychotics. Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress. September 30th ‐ October 4th; Venice, Italy. 1995. TollefsonG , BeasleyC , TranP , SangerT . Olanzapine: An exciting atypical antipsychotic. The clinical experience. Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress. September 30th ‐ October 4th; Venice, Italy. 1995. TollefsonG , SangerT , BeasleyC . The course of primary and secondary negative symptoms in a placebo‐and comparator‐controlled trial of the typical antipsychotic olanzapine. Proceedings of 9th ECNP (European College of Neuropsychopharmacology) Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. TollefsonGD . Olanzapine: A novel antipsychotic with a broad spectrum profile. Proceedings of XIXth Collegium Internationale Neuro‐psychopharmacologicum Congress. June 27th ‐ July 1st; Washington DC, USA. 1994. TollefsonGD . The value of atypical antipsychotic medications. Proceedings of 150th American Psychiatric Association Annual Meeting. San Diego, USA. 1997. TollefsonGD , BeasleyCM , TranPV , SangerT . [The next generation of antipsychotics]. Proceedings of 148th Annual Meeting of the American Psychiatric Association. May 20‐5th; Miami, USA. 1995. TollefsonGD , BeasleyCM , TranPV , SangerT . Olanzapine: A novel antipsychotic with a broad spectrum. Proceedings of 49th Annual Convention and Scientific Program of the Society of Biological Psychiatry. May 18‐22nd; Philadelphia, USA. 1994. TollefsonGD , SangerT , BeasleyCM . The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Proceedings of 149th American Psychiatric Association Annual Meeting. May 4‐9th. 1996. TollefsonGD , SangerTM . Negative symptoms: A path analytic approach to a double‐blind, placebo and haloperidol controlled clinical trial with olanzapine. American Journal of Psychiatry1997;154:466‐74. TollefsonGD , SangerTM , BeasleyCM . The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Proceedings of XXth Collegium Internationale Neuro‐psychopharmacologicum. June 23‐27th; Melbourne, Australia. 1996. TollefsonGD , SangerTM , BeasleyCM , TranPV . A double‐blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological Psychiatry1998;43:803‐10. TollefsonGD , SangerTM , BeasleyCM , TranPV . Is there a relationship between EPSE and efficacy: faction or fiction. Proceedings of Campaign on Schizophrenia. March 10‐12th; Florence, Italy. 1995. TranP , BeasleyC , TollefsonG , BeuzenJ , DellvaM , SangerT , eral . Acute and long‐term results of the North American double‐blind Olanzapine trial. Proceedings of 8th ECNP (European College of Neuropsychopharmacology) Congress. September 30th ‐ October 4th; Venice, Italy. 1995. TranP , BeasleyC , TollefsonG , DellvaM , HamiltonS , VanOstrandR , et al. Acute and long term results of the North American double‐blind olanzapine trial. Proceedings of 20th Collegium Internationale Neuropsychopharmacologicum Congress. June 23‐27th; Melbourne, Australia. 1996. TranP , DellvaM , RampeyV , TollefsonG , BeasleyC . Long‐term continuation therapy with the novel antipsychotic olanzapine: A review of the clinical experience. Proceedings of 9th ECNP (European College of Neuropsychopharmacology) Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. TranPV , BeasleyCM , TollefsonGD , SangerT , SatterleeWG . Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent. Proceedings of XIXth Collegium Internationale Neuro‐psychopharmacologicum Congress. June 27th ‐ July 1st; Washington DC, USA. 1994. WoodAJ , BeasleyCM , TollefsonGD , TranPV . [Efficacy of olanzapine in the post ive and negative symptoms of schizophrenia]. Proceedings of 7th Congress of the European College of Neuropsychopharmacology. October 16‐21st; Jerusalem, Israel. 1994. ">Beasley 1996</a>; <a href="./references#CD003082-bbs2-0010" title="HowardJ . Haloperidol for chronically hospitalised psychotics: A double‐blind comparison with thiothixene and placebo; a follow‐up open evaluation. Diseases of the Nervous System1974;35:458‐63. ">Howard 1974</a>; <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a>). Eleven studies were multi‐centre (<a href="./references#CD003082-bbs2-0001" title="ArvanitisLA , MillerBG . (ICI 204,636): An atypical antipsychotic: Results from a multiple fixed dose, placebo‐controlled study. Proceedings of XXth Collegium Internationale Neuro‐Psychopharmacologicum. June 23‐27th; Melbourne, Australia. 1996. ArvanitisLA , MillerBG . Quetiapine, an atypical antipsychotic ‐ results from a multiple fixed dose, placebo‐controlled study. Proceedings of 149th Annual Meeting American Psychiatric Association. May 4‐9th. 1996. ArvanitisLA , MillerBG , KowalcykBB . Efficacy of 'Seroquel' (Quetiapine Fumarate) in affective symptoms of schizophrenia). Proceedings of 36th Annual Meeting of the American College of Neuropsychopharmacology. December 8‐12th; Waikoloa, Hawai, USA. 1997. ArvanitisLA , MillerBG , Seroquel Trial 13 Study Group. Multiple fixed doses of &quot;Seroquel&quot; (Quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biological Psychiatry1997;42:233‐46. BorisonRL , ArvanitisLA , MillerBG . A comparison of five fixed doese of 'Seroquel' (ICI 204,636) with haloperidol and placebo in patients with schizophrenia. Proceedings of 8th Biennial Winter Workshop on Schizophrenia. March 16‐22nd; Crans Montana, Switzerland. 1996. BorisonRL , ArvantisLA , MillerBG . A multiple fixed‐dose, placebo‐controlled trial with 'Seroquel' ‐ An atypical antipsychotic. Biological Psychiatry1996;39:333. CantillonM . [Quetiapine fumarate reduces aggression]. Proceedings of the 11th Annual Meeting of the American Association of Geriatric Psychiatry; San Diego, California, USA. 1997. CantillonM , ArvanitisLA , MillerBG , Kowalcyk . 'Seroquel' (Quetiapine Fumarate) reduces hostility and aggression in patients with acute schizophrenia. Proceedings of 36th Annual Meeting of the American College of Neuropsychopharmacology. December 8‐12th; Waikoloa, Hawai, USA. 1997. CantillonM , GoldsteinJM . Efficacy of Quetiapine fumarate in affective symptoms of schizophrenia. Proceedings of American Psychiatric Association Annual Meeting. May 30th‐June 4th; Toronto, Ontario, Canada. 1998. HellewellJSE , Cameron‐HandsD , CantillonM . Seroquel: Evidence for efficacy in the treatment of hostility and aggression. 9th Biennial Winter Workshop on Schizophrenia. February 7‐13th; Davos, Switzerland. 1998. HongW , ArvanitisL . Reduction of the positive symptoms of schizophrenia by (ICI 204,636): Results from phase II and III clinical trials. Proceedings of 9th European College of Neuropsychopharmacology Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. HongWW , ArvanitisL . The atypical profile of (ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic patients. Proceedings of the 9th European College of Neuropsychopharmacology Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. HongWW , ArvanitisLA , MillerBG . (ICI 204,636) does not differ from placebo in the incidence of EPS or effect on plasma prolactin. Proceedings of the XXth Collegium Internationale Neuro‐psychopharmacologicum. June 23‐27th; Melbourne, Australia. 1996. HongWW , ArvanitisLA , MillerBG . Quetiapine does not differ from placebo in the incidence of extrapyramidal syndrome of effect on plasma prolactin. Proceedings of the 149th Annual Meeting American Psychiatric Association. May 4‐9th. 1996. ">Arvanitis 1997</a>; <a href="./references#CD003082-bbs2-0002" title="Ascher‐SvanumH , StenslandMD , KinonBJ , TollefsonGD . Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. Journal of Psychopharmacology2005;19(6 Suppl):110‐7. [MEDLINE: 16280344] BeasleyC , TollefsonGD , BeuzenJN , DellvaMA , SangerTM , PaulS . Acute and long‐term results of the North American double‐blind olanzapine trial. Proceedings of the 4th International Conference. October 6‐9th; Vancouver BC, Canada. 1996. BeasleyCM , TollefsonG , TranP , SatterleeW , SangerT , HamiltonS , Olanzapine HGAD study group. Olanzapine versus placebo and haloperidol; Acute phase results of the North American double‐blind olanzapine trial. Neuropsychopharmacology1996;14:111‐23. BeasleyCM , TollefsonGD , TranPV . Efficacy of Olanzapine: An overview of pivotal clinical trials. Journal of Clinical Psychiatry1997;58:7‐12. CrawfordAMK , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research1997;26:41‐54. HamiltonSH , RevickiDA , GendusoLA , BeasleyCM . Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double‐blind trial. Neuropsychopharmacology1998;18:41‐9. PerryPJ , LundBC , SangerT , BeasleyC . Olanzapine plasma concentrations and clinical response: Acute phase results of the North American Olanzapine trial. Journal of Clinical Psychopharmacology2001;21:14‐20. RevickiD , GendusoL . Effect of Olanzapine on deficit syndrome symptoms in chronic schizophrenia. Proceedings of 8th ECNP (European College of Neuropsychopharmacology) Congress; September 30th ‐ October 4th; Venice, Italy. 1997. SangerT , TollefsonGD . A controlled study on the course of primary and secondary negative symptoms. Proceedings of 150th American Psychiatric Association Annual Meeting. San Diego, USA. 1997. SatterleeW , BeasleyC , SangerT , TranP , TollefsonG . Olanzapine, a new atypical antipsychotic. Proceedings of 5th International Congress on Schizophrenia Research. April 6‐12th; Wormsprings, USA. 1996. TollefsonG . Update on new atypical antipsychotics. Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress. September 30th ‐ October 4th; Venice, Italy. 1995. TollefsonG , BeasleyC , TranP , SangerT . Olanzapine: An exciting atypical antipsychotic. The clinical experience. Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress. September 30th ‐ October 4th; Venice, Italy. 1995. TollefsonG , SangerT , BeasleyC . The course of primary and secondary negative symptoms in a placebo‐and comparator‐controlled trial of the typical antipsychotic olanzapine. Proceedings of 9th ECNP (European College of Neuropsychopharmacology) Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. TollefsonGD . Olanzapine: A novel antipsychotic with a broad spectrum profile. Proceedings of XIXth Collegium Internationale Neuro‐psychopharmacologicum Congress. June 27th ‐ July 1st; Washington DC, USA. 1994. TollefsonGD . The value of atypical antipsychotic medications. Proceedings of 150th American Psychiatric Association Annual Meeting. San Diego, USA. 1997. TollefsonGD , BeasleyCM , TranPV , SangerT . [The next generation of antipsychotics]. Proceedings of 148th Annual Meeting of the American Psychiatric Association. May 20‐5th; Miami, USA. 1995. TollefsonGD , BeasleyCM , TranPV , SangerT . Olanzapine: A novel antipsychotic with a broad spectrum. Proceedings of 49th Annual Convention and Scientific Program of the Society of Biological Psychiatry. May 18‐22nd; Philadelphia, USA. 1994. TollefsonGD , SangerT , BeasleyCM . The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Proceedings of 149th American Psychiatric Association Annual Meeting. May 4‐9th. 1996. TollefsonGD , SangerTM . Negative symptoms: A path analytic approach to a double‐blind, placebo and haloperidol controlled clinical trial with olanzapine. American Journal of Psychiatry1997;154:466‐74. TollefsonGD , SangerTM , BeasleyCM . The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Proceedings of XXth Collegium Internationale Neuro‐psychopharmacologicum. June 23‐27th; Melbourne, Australia. 1996. TollefsonGD , SangerTM , BeasleyCM , TranPV . A double‐blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological Psychiatry1998;43:803‐10. TollefsonGD , SangerTM , BeasleyCM , TranPV . Is there a relationship between EPSE and efficacy: faction or fiction. Proceedings of Campaign on Schizophrenia. March 10‐12th; Florence, Italy. 1995. TranP , BeasleyC , TollefsonG , BeuzenJ , DellvaM , SangerT , eral . Acute and long‐term results of the North American double‐blind Olanzapine trial. Proceedings of 8th ECNP (European College of Neuropsychopharmacology) Congress. September 30th ‐ October 4th; Venice, Italy. 1995. TranP , BeasleyC , TollefsonG , DellvaM , HamiltonS , VanOstrandR , et al. Acute and long term results of the North American double‐blind olanzapine trial. Proceedings of 20th Collegium Internationale Neuropsychopharmacologicum Congress. June 23‐27th; Melbourne, Australia. 1996. TranP , DellvaM , RampeyV , TollefsonG , BeasleyC . Long‐term continuation therapy with the novel antipsychotic olanzapine: A review of the clinical experience. Proceedings of 9th ECNP (European College of Neuropsychopharmacology) Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. TranPV , BeasleyCM , TollefsonGD , SangerT , SatterleeWG . Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent. Proceedings of XIXth Collegium Internationale Neuro‐psychopharmacologicum Congress. June 27th ‐ July 1st; Washington DC, USA. 1994. WoodAJ , BeasleyCM , TollefsonGD , TranPV . [Efficacy of olanzapine in the post ive and negative symptoms of schizophrenia]. Proceedings of 7th Congress of the European College of Neuropsychopharmacology. October 16‐21st; Jerusalem, Israel. 1994. ">Beasley 1996</a>; <a href="./references#CD003082-bbs2-0004" title="BorisonRL , SinahD , HaverstockS , McLarnonMC , DiamondB . Efficacy and safety of tiospirone vs haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989;25:190‐3. ">Borison 1989</a>; <a href="./references#CD003082-bbs2-0006" title="ChouinardG . Effects of risperidone in tardive dyskinesia: An analysis of the Canadian multicentre risperidone study. Journal of Clinical Psychopharmacology1995;15:S36‐44. ChouinardG , AlbrightP . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17:298‐307. ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Proceedings 47th Annual Convention and Scientific Program of the Society of Biological Psychiatry. April 29th ‐ May 3rd; Washington DC, USA. 1992. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian Multicentre placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13:25‐40. ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. Proceedings of 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress. June 27th ‐ July 1st; Washington DC, USA. 1994. ChouindardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Proceedings of 18th Collegium Internationale Neuro‐Psychopharmacologicum Congress. June 28th ‐ July 2nd; Nice, France. 1992. NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. http://www.clinicaltrials.gov2005. ">Chouinard 1993</a>; <a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a>; <a href="./references#CD003082-bbs2-0012" title="AnutoshS , AliMW , IngenitoG , CarsonWH . Controlled study of aripiprazole and haloperidol in schizophrenia. 11th Association of European Psychiatrists Congress. May 4‐8, Stockholm, Sweden. 2002. CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 13th Congress of the European College of Neuropsychopharmacology [CD‐ROM]: Conifer Excerpta Medica Medical Communications BV. P2075. 2000. DanielD , StockE , WilberC , MarcusR , CarsonWHJr , ManosG , et al. Intramuscular Aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association. May 1‐6; New York, USA. 2004. KaneJM , CarsonWH , SahaAR , McQuadeRD , IngenitoGG , ZimbroffDL , et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry2002;63(9):763‐71. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychoitc disorders: comparison with haloperidol and placebo. 153rd Annual Meeting of the American Psychiatric Association. May 13‐8; Chicago, USA. 2000. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 155th Annual Meeting of the American Psychiatric Association. May 18‐23; Philadelphia, PA, USA. 2002. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Abstracts of the XII CINP Congress, Brussels, Belgium, July 9‐13. 2000. ">Kane 2002</a>; <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a>; <a href="./references#CD003082-bbs2-0015" title="MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151:825‐35. ">Marder 1994</a>; <a href="./references#CD003082-bbs2-0016" title="MeltzerHY . Testing multiple novel mechanisms for treating schizophrenia in a single trial. In: CummingsJL editor(s). Progress in Neurotherapeutics and Neuropsychopharmacology. New York, NY, US: Cambridge University Press, 2006:115‐20. Meltzer , HY , ArvanitisL , BauerD , Rein W and Meta‐trial Study Group. Placebo‐controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. American Journal of Psychiatry2004;161(6):975‐84. ">Meltzer 2004</a>; <a href="./references#CD003082-bbs2-0017" title="NCT00044044 . A 6‐week, double‐blind, randomized, fixed‐dose, parallel‐group study of the efficacy and safety of three dose levels of SM‐13496 compared to placebo and haloperidol in patients with schizophrenia who are experiencing an acute exacerbation of symptoms. www.ClinicalTrials.gov (accessed on 30 Oct 2012).2002. ">NCT00044044 2002</a>; <a href="./references#CD003082-bbs2-0020" title="PotkinSG , LitmanRE , TorresR , WolfgangCD . Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. Journal of Clinical Psychopharmacology2008;28(2 Suppl 1):S4‐S11. ">Potkin 2008</a>). </p> </section> <section id="CD003082-sec-0105"> <h5 class="title">5. Study size</h5> <p>The included studies involved 4651 participants. The largest trial (<a href="./references#CD003082-bbs2-0020" title="PotkinSG , LitmanRE , TorresR , WolfgangCD . Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. Journal of Clinical Psychopharmacology2008;28(2 Suppl 1):S4‐S11. ">Potkin 2008</a>) randomised 621 people (although this review only uses data for the haloperidol (n = 124) and placebo groups (n = 127)), while the smallest study included only 12 participants (<a href="./references#CD003082-bbs2-0024" title="SpencerE , AlpertM , PougetE . Scales for the assessment of neuroleptic response in schizophrenic children: Specific measures derived from the CPRS. Psychopharmacology Bulletin1994;30:199‐202. SpencerEK , AlpertM , PougetER . [Two sensitive and specific scales derived from the CPRS for assessing haloperidol response in hospitalised schizophrenic children]. Proceedings of 33rd Annual Meeting of the New Clinical Drug Evaluation Unit. June 1‐4th; Boca Raton, USA. 1993. SpencerEK , KafantarisV , Padron‐GayolMV , RosenbergCR , CampbellM . Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacology Bulletin1992;28:183‐6. ">Spencer 1992</a>). Seven of the 25 studies randomised fewer than 50 people and 11 were greater than 100. Nine of these randomised over 300 participants (<a href="./references#CD003082-bbs2-0001" title="ArvanitisLA , MillerBG . (ICI 204,636): An atypical antipsychotic: Results from a multiple fixed dose, placebo‐controlled study. Proceedings of XXth Collegium Internationale Neuro‐Psychopharmacologicum. June 23‐27th; Melbourne, Australia. 1996. ArvanitisLA , MillerBG . Quetiapine, an atypical antipsychotic ‐ results from a multiple fixed dose, placebo‐controlled study. Proceedings of 149th Annual Meeting American Psychiatric Association. May 4‐9th. 1996. ArvanitisLA , MillerBG , KowalcykBB . Efficacy of 'Seroquel' (Quetiapine Fumarate) in affective symptoms of schizophrenia). Proceedings of 36th Annual Meeting of the American College of Neuropsychopharmacology. December 8‐12th; Waikoloa, Hawai, USA. 1997. ArvanitisLA , MillerBG , Seroquel Trial 13 Study Group. Multiple fixed doses of &quot;Seroquel&quot; (Quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biological Psychiatry1997;42:233‐46. BorisonRL , ArvanitisLA , MillerBG . A comparison of five fixed doese of 'Seroquel' (ICI 204,636) with haloperidol and placebo in patients with schizophrenia. Proceedings of 8th Biennial Winter Workshop on Schizophrenia. March 16‐22nd; Crans Montana, Switzerland. 1996. BorisonRL , ArvantisLA , MillerBG . A multiple fixed‐dose, placebo‐controlled trial with 'Seroquel' ‐ An atypical antipsychotic. Biological Psychiatry1996;39:333. CantillonM . [Quetiapine fumarate reduces aggression]. Proceedings of the 11th Annual Meeting of the American Association of Geriatric Psychiatry; San Diego, California, USA. 1997. CantillonM , ArvanitisLA , MillerBG , Kowalcyk . 'Seroquel' (Quetiapine Fumarate) reduces hostility and aggression in patients with acute schizophrenia. Proceedings of 36th Annual Meeting of the American College of Neuropsychopharmacology. December 8‐12th; Waikoloa, Hawai, USA. 1997. CantillonM , GoldsteinJM . Efficacy of Quetiapine fumarate in affective symptoms of schizophrenia. Proceedings of American Psychiatric Association Annual Meeting. May 30th‐June 4th; Toronto, Ontario, Canada. 1998. HellewellJSE , Cameron‐HandsD , CantillonM . Seroquel: Evidence for efficacy in the treatment of hostility and aggression. 9th Biennial Winter Workshop on Schizophrenia. February 7‐13th; Davos, Switzerland. 1998. HongW , ArvanitisL . Reduction of the positive symptoms of schizophrenia by (ICI 204,636): Results from phase II and III clinical trials. Proceedings of 9th European College of Neuropsychopharmacology Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. HongWW , ArvanitisL . The atypical profile of (ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic patients. Proceedings of the 9th European College of Neuropsychopharmacology Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. HongWW , ArvanitisLA , MillerBG . (ICI 204,636) does not differ from placebo in the incidence of EPS or effect on plasma prolactin. Proceedings of the XXth Collegium Internationale Neuro‐psychopharmacologicum. June 23‐27th; Melbourne, Australia. 1996. HongWW , ArvanitisLA , MillerBG . Quetiapine does not differ from placebo in the incidence of extrapyramidal syndrome of effect on plasma prolactin. Proceedings of the 149th Annual Meeting American Psychiatric Association. May 4‐9th. 1996. ">Arvanitis 1997</a>; <a href="./references#CD003082-bbs2-0002" title="Ascher‐SvanumH , StenslandMD , KinonBJ , TollefsonGD . Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. Journal of Psychopharmacology2005;19(6 Suppl):110‐7. [MEDLINE: 16280344] BeasleyC , TollefsonGD , BeuzenJN , DellvaMA , SangerTM , PaulS . Acute and long‐term results of the North American double‐blind olanzapine trial. Proceedings of the 4th International Conference. October 6‐9th; Vancouver BC, Canada. 1996. BeasleyCM , TollefsonG , TranP , SatterleeW , SangerT , HamiltonS , Olanzapine HGAD study group. Olanzapine versus placebo and haloperidol; Acute phase results of the North American double‐blind olanzapine trial. Neuropsychopharmacology1996;14:111‐23. BeasleyCM , TollefsonGD , TranPV . Efficacy of Olanzapine: An overview of pivotal clinical trials. Journal of Clinical Psychiatry1997;58:7‐12. CrawfordAMK , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research1997;26:41‐54. HamiltonSH , RevickiDA , GendusoLA , BeasleyCM . Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double‐blind trial. Neuropsychopharmacology1998;18:41‐9. PerryPJ , LundBC , SangerT , BeasleyC . Olanzapine plasma concentrations and clinical response: Acute phase results of the North American Olanzapine trial. Journal of Clinical Psychopharmacology2001;21:14‐20. RevickiD , GendusoL . Effect of Olanzapine on deficit syndrome symptoms in chronic schizophrenia. Proceedings of 8th ECNP (European College of Neuropsychopharmacology) Congress; September 30th ‐ October 4th; Venice, Italy. 1997. SangerT , TollefsonGD . A controlled study on the course of primary and secondary negative symptoms. Proceedings of 150th American Psychiatric Association Annual Meeting. San Diego, USA. 1997. SatterleeW , BeasleyC , SangerT , TranP , TollefsonG . Olanzapine, a new atypical antipsychotic. Proceedings of 5th International Congress on Schizophrenia Research. April 6‐12th; Wormsprings, USA. 1996. TollefsonG . Update on new atypical antipsychotics. Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress. September 30th ‐ October 4th; Venice, Italy. 1995. TollefsonG , BeasleyC , TranP , SangerT . Olanzapine: An exciting atypical antipsychotic. The clinical experience. Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress. September 30th ‐ October 4th; Venice, Italy. 1995. TollefsonG , SangerT , BeasleyC . The course of primary and secondary negative symptoms in a placebo‐and comparator‐controlled trial of the typical antipsychotic olanzapine. Proceedings of 9th ECNP (European College of Neuropsychopharmacology) Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. TollefsonGD . Olanzapine: A novel antipsychotic with a broad spectrum profile. Proceedings of XIXth Collegium Internationale Neuro‐psychopharmacologicum Congress. June 27th ‐ July 1st; Washington DC, USA. 1994. TollefsonGD . The value of atypical antipsychotic medications. Proceedings of 150th American Psychiatric Association Annual Meeting. San Diego, USA. 1997. TollefsonGD , BeasleyCM , TranPV , SangerT . [The next generation of antipsychotics]. Proceedings of 148th Annual Meeting of the American Psychiatric Association. May 20‐5th; Miami, USA. 1995. TollefsonGD , BeasleyCM , TranPV , SangerT . Olanzapine: A novel antipsychotic with a broad spectrum. Proceedings of 49th Annual Convention and Scientific Program of the Society of Biological Psychiatry. May 18‐22nd; Philadelphia, USA. 1994. TollefsonGD , SangerT , BeasleyCM . The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Proceedings of 149th American Psychiatric Association Annual Meeting. May 4‐9th. 1996. TollefsonGD , SangerTM . Negative symptoms: A path analytic approach to a double‐blind, placebo and haloperidol controlled clinical trial with olanzapine. American Journal of Psychiatry1997;154:466‐74. TollefsonGD , SangerTM , BeasleyCM . The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Proceedings of XXth Collegium Internationale Neuro‐psychopharmacologicum. June 23‐27th; Melbourne, Australia. 1996. TollefsonGD , SangerTM , BeasleyCM , TranPV . A double‐blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological Psychiatry1998;43:803‐10. TollefsonGD , SangerTM , BeasleyCM , TranPV . Is there a relationship between EPSE and efficacy: faction or fiction. Proceedings of Campaign on Schizophrenia. March 10‐12th; Florence, Italy. 1995. TranP , BeasleyC , TollefsonG , BeuzenJ , DellvaM , SangerT , eral . Acute and long‐term results of the North American double‐blind Olanzapine trial. Proceedings of 8th ECNP (European College of Neuropsychopharmacology) Congress. September 30th ‐ October 4th; Venice, Italy. 1995. TranP , BeasleyC , TollefsonG , DellvaM , HamiltonS , VanOstrandR , et al. Acute and long term results of the North American double‐blind olanzapine trial. Proceedings of 20th Collegium Internationale Neuropsychopharmacologicum Congress. June 23‐27th; Melbourne, Australia. 1996. TranP , DellvaM , RampeyV , TollefsonG , BeasleyC . Long‐term continuation therapy with the novel antipsychotic olanzapine: A review of the clinical experience. Proceedings of 9th ECNP (European College of Neuropsychopharmacology) Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. TranPV , BeasleyCM , TollefsonGD , SangerT , SatterleeWG . Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent. Proceedings of XIXth Collegium Internationale Neuro‐psychopharmacologicum Congress. June 27th ‐ July 1st; Washington DC, USA. 1994. WoodAJ , BeasleyCM , TollefsonGD , TranPV . [Efficacy of olanzapine in the post ive and negative symptoms of schizophrenia]. Proceedings of 7th Congress of the European College of Neuropsychopharmacology. October 16‐21st; Jerusalem, Israel. 1994. ">Beasley 1996</a>; <a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a>; <a href="./references#CD003082-bbs2-0012" title="AnutoshS , AliMW , IngenitoG , CarsonWH . Controlled study of aripiprazole and haloperidol in schizophrenia. 11th Association of European Psychiatrists Congress. May 4‐8, Stockholm, Sweden. 2002. CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 13th Congress of the European College of Neuropsychopharmacology [CD‐ROM]: Conifer Excerpta Medica Medical Communications BV. P2075. 2000. DanielD , StockE , WilberC , MarcusR , CarsonWHJr , ManosG , et al. Intramuscular Aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association. May 1‐6; New York, USA. 2004. KaneJM , CarsonWH , SahaAR , McQuadeRD , IngenitoGG , ZimbroffDL , et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry2002;63(9):763‐71. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychoitc disorders: comparison with haloperidol and placebo. 153rd Annual Meeting of the American Psychiatric Association. May 13‐8; Chicago, USA. 2000. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 155th Annual Meeting of the American Psychiatric Association. May 18‐23; Philadelphia, PA, USA. 2002. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Abstracts of the XII CINP Congress, Brussels, Belgium, July 9‐13. 2000. ">Kane 2002</a>; <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a>; <a href="./references#CD003082-bbs2-0015" title="MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151:825‐35. ">Marder 1994</a>; <a href="./references#CD003082-bbs2-0016" title="MeltzerHY . Testing multiple novel mechanisms for treating schizophrenia in a single trial. In: CummingsJL editor(s). Progress in Neurotherapeutics and Neuropsychopharmacology. New York, NY, US: Cambridge University Press, 2006:115‐20. Meltzer , HY , ArvanitisL , BauerD , Rein W and Meta‐trial Study Group. Placebo‐controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. American Journal of Psychiatry2004;161(6):975‐84. ">Meltzer 2004</a>; <a href="./references#CD003082-bbs2-0017" title="NCT00044044 . A 6‐week, double‐blind, randomized, fixed‐dose, parallel‐group study of the efficacy and safety of three dose levels of SM‐13496 compared to placebo and haloperidol in patients with schizophrenia who are experiencing an acute exacerbation of symptoms. www.ClinicalTrials.gov (accessed on 30 Oct 2012).2002. ">NCT00044044 2002</a>; <a href="./references#CD003082-bbs2-0020" title="PotkinSG , LitmanRE , TorresR , WolfgangCD . Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. Journal of Clinical Psychopharmacology2008;28(2 Suppl 1):S4‐S11. ">Potkin 2008</a>). </p> </section> <section id="CD003082-sec-0106"> <h5 class="title">6. Interventions</h5> <p>A wide range of doses of haloperidol was used in the trials. The smallest doses were given in <a href="./references#CD003082-bbs2-0024" title="SpencerE , AlpertM , PougetE . Scales for the assessment of neuroleptic response in schizophrenic children: Specific measures derived from the CPRS. Psychopharmacology Bulletin1994;30:199‐202. SpencerEK , AlpertM , PougetER . [Two sensitive and specific scales derived from the CPRS for assessing haloperidol response in hospitalised schizophrenic children]. Proceedings of 33rd Annual Meeting of the New Clinical Drug Evaluation Unit. June 1‐4th; Boca Raton, USA. 1993. SpencerEK , KafantarisV , Padron‐GayolMV , RosenbergCR , CampbellM . Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacology Bulletin1992;28:183‐6. ">Spencer 1992</a> who used a range of 0.5 to 10 mg/day for children under 12 years of age and the greatest in <a href="./references#CD003082-bbs2-0010" title="HowardJ . Haloperidol for chronically hospitalised psychotics: A double‐blind comparison with thiothixene and placebo; a follow‐up open evaluation. Diseases of the Nervous System1974;35:458‐63. ">Howard 1974</a> (doses up to 200 mg/day). Most studies used doses in the range of 4 mg/day to 20 mg/day. The majority of trials adjusted the dose according to need with only seven studies appearing to give a fixed dose throughout the trial (<a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a>; <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a>; <a href="./references#CD003082-bbs2-0014" title="KlieserE , LehmannE . Experimental examination of trazodone. Clinical Neuropharmacology1989;12:S18‐24. ">Klieser 1989</a>; <a href="./references#CD003082-bbs2-0015" title="MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151:825‐35. ">Marder 1994</a>; <a href="./references#CD003082-bbs2-0020" title="PotkinSG , LitmanRE , TorresR , WolfgangCD . Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. Journal of Clinical Psychopharmacology2008;28(2 Suppl 1):S4‐S11. ">Potkin 2008</a>; <a href="./references#CD003082-bbs2-0023" title="SimpsonGM , AngusJWS , EdwardsJG . A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research1967;9:407‐12. ">Simpson 1967</a>; <a href="./references#CD003082-bbs2-0025" title="VichaiyaV . Clinical trial of haloperidol in schizophrenia. Journal of Psychiatric Association of Thailand1971;16(1):31‐43. ">Vichaiya 1971</a>). Most trials randomised to other drugs in addition to placebo. The other comparators included amitriptyline, asenapine, blonanserin, chlorpromazine, clopenthixol, diazepam, iloperidone, imipramine, loxapine, lurasidone, olanzapine, quetiapine, risperidone, thioridazine, thiothixene, trazodone and one trial (<a href="./references#CD003082-bbs2-0016" title="MeltzerHY . Testing multiple novel mechanisms for treating schizophrenia in a single trial. In: CummingsJL editor(s). Progress in Neurotherapeutics and Neuropsychopharmacology. New York, NY, US: Cambridge University Press, 2006:115‐20. Meltzer , HY , ArvanitisL , BauerD , Rein W and Meta‐trial Study Group. Placebo‐controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. American Journal of Psychiatry2004;161(6):975‐84. ">Meltzer 2004</a>) also evaluated four receptor antagonists (5‐HT<sub>2A/2C</sub>, NK<sub>3</sub>, CB<sub>1</sub> and NTS<sub>1</sub> antagonists). Only six studies had the single comparison of haloperidol with placebo (<a href="./references#CD003082-bbs2-0003" title="BechelliLPC , Ruffino‐NettoA , HetemG . A double‐blind controlled trial of pipotiazine, haloperidol and placebo in recently hospitalised acute schizophrenic patients. Brazilian Journal of Biological Research1983;16:305‐11. ">Bechelli 1983</a>; <a href="./references#CD003082-bbs2-0007" title="DurostH , LeeH , ArthursD . An early evaluation of Haloperidol. The Butyrophenones in Psychiatry. Edited by HE Lehmann and TA Ban. Channel Press Inc, 1964:70‐3. ">Durost 1964</a>; <a href="./references#CD003082-bbs2-0009" title="GarryJW , LeonardTJ . Haloperidol: A controlled trial in chronic schizophrenia. British Journal of Psychiatry1962;108:105‐7. ">Garry 1962</a>; <a href="./references#CD003082-bbs2-0011" title="JannMW , CrabtreeBL , PittsWM , Francis LamYW , CarterJG . Plasma alpha‐one acid glycoprotein and haloperidol concentrations in schizophrenic patients. Neuropsychobiology1997;36:32‐6. ">Jann 1997</a>; <a href="./references#CD003082-bbs2-0024" title="SpencerE , AlpertM , PougetE . Scales for the assessment of neuroleptic response in schizophrenic children: Specific measures derived from the CPRS. Psychopharmacology Bulletin1994;30:199‐202. SpencerEK , AlpertM , PougetER . [Two sensitive and specific scales derived from the CPRS for assessing haloperidol response in hospitalised schizophrenic children]. Proceedings of 33rd Annual Meeting of the New Clinical Drug Evaluation Unit. June 1‐4th; Boca Raton, USA. 1993. SpencerEK , KafantarisV , Padron‐GayolMV , RosenbergCR , CampbellM . Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacology Bulletin1992;28:183‐6. ">Spencer 1992</a>; <a href="./references#CD003082-bbs2-0025" title="VichaiyaV . Clinical trial of haloperidol in schizophrenia. Journal of Psychiatric Association of Thailand1971;16(1):31‐43. ">Vichaiya 1971</a>). Of these <a href="./references#CD003082-bbs2-0025" title="VichaiyaV . Clinical trial of haloperidol in schizophrenia. Journal of Psychiatric Association of Thailand1971;16(1):31‐43. ">Vichaiya 1971</a> and <a href="./references#CD003082-bbs2-0024" title="SpencerE , AlpertM , PougetE . Scales for the assessment of neuroleptic response in schizophrenic children: Specific measures derived from the CPRS. Psychopharmacology Bulletin1994;30:199‐202. SpencerEK , AlpertM , PougetER . [Two sensitive and specific scales derived from the CPRS for assessing haloperidol response in hospitalised schizophrenic children]. Proceedings of 33rd Annual Meeting of the New Clinical Drug Evaluation Unit. June 1‐4th; Boca Raton, USA. 1993. SpencerEK , KafantarisV , Padron‐GayolMV , RosenbergCR , CampbellM . Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacology Bulletin1992;28:183‐6. ">Spencer 1992</a> were cross‐over trials. Fourteen studies stated that they used other medications to alleviate adverse effects or behaviour as required. These drugs included benztropine mesylate, biperiden, chloral hydrate, lorazepam, nitrazepam, paraldehyde, procyclidine, sodium amytal and trihexyphenidyl. </p> </section> <section id="CD003082-sec-0107"> <h5 class="title">7. Outcomes</h5> <section id="CD003082-sec-0108"> <h6 class="title">7.1 Missing outcomes</h6> <p>None of the studies evaluated patient or staff satisfaction. Death, suicide or self‐harm was also not mentioned in any study. Outcomes such as employment status, living status and community burden were not investigated in the included studies, nor were economic outcomes such as cost of care. </p> </section> <section id="CD003082-sec-0109"> <h6 class="title">7.2 Scales</h6> <p>Twenty different instruments were used to collect data. Although all of the scales used were validated through peer review, only seven collected continuous data useful to this review. Details of the scales are shown below. Reasons for exclusion of data from the other instruments are given in the <a href="./references#CD003082-sec-0198" title="">Characteristics of included studies</a>. Frequently, despite using a scale, no data were presented, or means were reported without a variance. </p> <section id="CD003082-sec-0110"> <p><b>7.2.1 Mental state</b></p> <p>i. Brief Psychiatric Rating Scale ‐ BPRS (<a href="./references#CD003082-bbs2-0168" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>)<br/> This is used to assess the severity of abnormal mental state. The original scale has 16 items, but a revised 18‐item scale is commonly used. Each item is defined on a seven‐point scale varying from 'not present' to 'extremely severe', scoring from zero to six or one to seven. Scores can range from zero to 126, with high scores indicating more severe symptoms. <a href="./references#CD003082-bbs2-0003" title="BechelliLPC , Ruffino‐NettoA , HetemG . A double‐blind controlled trial of pipotiazine, haloperidol and placebo in recently hospitalised acute schizophrenic patients. Brazilian Journal of Biological Research1983;16:305‐11. ">Bechelli 1983</a>, <a href="./references#CD003082-bbs2-0005" title="BorisonR , PathiragaA , DiamondB , MeibachR . Risperidone and Schizophrenia. Proceedings of 5th World Congress of Biological Psychiatry. June 9‐14th; Florence, Italy. 1991. BorisonRL , DiamondBI , AugustaGA . Serotonin modulation of dopaminergic‐medicated extrapyramidal side effects. Proceedings of 43rd Annual Meeting of the American Academy of Neurology. April 21‐27th; Boston, USA. 1991. BorisonRL , DiamondBI , PathirajaA , MeibachRC . Clinical profile of risperidone in chronic schizophrenia. Proceedings of 17th Congress of Collegium Internationale Neuro‐psychopharmacologicum. 1993. BorisonRL , PathirajaAP , DiamondB , MeibachRC . Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin1992;28:213‐8. ">Borison 1992a</a>, <a href="./references#CD003082-bbs2-0011" title="JannMW , CrabtreeBL , PittsWM , Francis LamYW , CarterJG . Plasma alpha‐one acid glycoprotein and haloperidol concentrations in schizophrenic patients. Neuropsychobiology1997;36:32‐6. ">Jann 1997</a> and <a href="./references#CD003082-bbs2-0014" title="KlieserE , LehmannE . Experimental examination of trazodone. Clinical Neuropharmacology1989;12:S18‐24. ">Klieser 1989</a> reported data from this scale. </p> <p>ii. Calgary Depression Scale ‐ CDS (<a href="./references#CD003082-bbs2-0136" title="AddingtonD ,  AddingtonJ ,  SchisselB . A depression rating scale for schizophrenics. Schizophrophrenia Research1990 Jul‐Aug;3(4):247‐51. ">Addington 1990</a>)<br/> The CDS is a nine‐item special purpose scale designed to measure depression in patients with chronic schizophrenia. Each item is rated from zero ‐ absent to three ‐severe. <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a> reported data from this scale. </p> <p>iii. Positive and Negative Syndrome Scale ‐ PANSS (<a href="./references#CD003082-bbs2-0162" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>)<br/> This schizophrenia scale has 30 items, each of which can be defined on a seven‐point scoring system varying from one (absent) to seven (extreme). This scale can be divided into three sub‐scales for measuring the severity of general psychopathology, positive symptoms (PANSS‐P), and negative symptoms (PANSS‐N). A low score indicates lesser severity. <a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a> and <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a> reported data from this scale. </p> </section> <section id="CD003082-sec-0111"> <p><b>7.2.2 Global state</b></p> <p>i. Clinical Global Impression – CGI (<a href="./references#CD003082-bbs2-0157" title="GuyU . Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology. National Institute of Mental Health1976. ">Guy 1976</a>)<br/> A rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement. A seven‐point scoring system is usually used with low scores indicating decreased severity and/or greater recovery. <a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a> and <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a> reported data from this scale. </p> </section> <section id="CD003082-sec-0112"> <p><b>7.2.3 Adverse effects</b></p> <p>i. Simpson‐Angus Scale ‐ SAS (<a href="./references#CD003082-bbs2-0172" title="SimpsonGM , AngusJW . A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica1970;212(suppl):11‐9. ">Simpson 1970</a>)<br/> This scale was employed to measure extrapyramidal symptoms. The 10‐item SAS is used to evaluate the presence and severity of parkinsonian symptomatology and other extrapyramidal effects. Higher scores reflect more adverse effects. This scale was used by <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a>. </p> <p>ii. Barnes Akathisia Scale – BAS (<a href="./references#CD003082-bbs2-0141" title="BarnesTR . A rating scale for drug‐induced akathisia. British Journal of Psychiatry1989;154:672‐6. ">Barnes 1989</a>)<br/> This is a 12‐item scale consisting of a standardised examination followed by questions rating the orofacial, extremity and trunk movements, as well as three global measurements. Each of these 10 items can be scored from zero (none) to four (severe). Two additional items assess the dental status. The BAS ranges from zero to 40, with higher scores indicating greater severity. This scale was used by <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a>. </p> <p>iii. Abnormal Involuntary Movement Scale ‐ AIMS (<a href="./references#CD003082-bbs2-0157" title="GuyU . Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology. National Institute of Mental Health1976. ">Guy 1976</a>)<br/> This is a 12‐item clinician‐rated scale to assess severity of dyskinesias (specifically, orofacial movements and extremity and truncal movements) in patients taking neuroleptic medications. Items are scored on a scale of zero (none) to four (severe) basis; the scale provides a total score (items one through seven) or item eight can be used in isolation as an indication of overall severity of symptoms. This scale was used by <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a>. </p> </section> </section> </section> <section id="CD003082-sec-0113"> <h5 class="title">Ongoing trials</h5> <p>As far as we are aware, there are currently no ongoing trials evaluating oral haloperidol versus placebo. </p> </section> <section id="CD003082-sec-0114"> <h5 class="title">Studies awaiting assessment</h5> <p>There are currently no studies awaiting assessment.</p> </section> </section> <section id="CD003082-sec-0115"> <h4 class="title">Excluded studies</h4> <p>Of the 109 excluded studies, we excluded 24 because they were not randomised and/or allocation was unclear. We excluded another nine because the participants were not suffering from schizophrenia. We excluded 31 because they compared haloperidol with another antipsychotic without a placebo group. We excluded seven studies because they administered haloperidol by intramuscular injection, not orally. We excluded five more studies because they were withdrawal trials. In these trials, people stable on haloperidol were randomised to placebo or to continue their usual dose of haloperidol. As this review is, at present, focusing on instigation studies of haloperidol, we excluded these trials. We eventually excluded a further 22 studies because all outcome data were impossible to use. Seven of these were only published as conference proceedings and information was not available in the short abstract. We have contacted the authors of these studies for additional data and this data may be included in later versions of this review. We excluded one cross‐over study (<a href="./references#CD003082-bbs2-0112" title="ReesL , DaviesB . A study of the value of haloperidol in the management and treatment of schizophrenic and manic patients. International Journal of Neuropsychiatry1965;1(3):263‐6. ">Rees 1965</a>) as no data were provided for the first arm of the trial. Three studies had losses to follow‐up greater than 50%, but data could not be added for leaving the study early: <a href="./references#CD003082-bbs2-0134" title='BakerR , MackR , MorrisD , SebreeT , KashkinK . The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients. Proceedings of 9th ENCP (European College of Neuropsychopharmacology) Congress; September 21‐25th; Amsterdam, The Netherlands. 1996. BechP , TanghojP , AndreassonKT , OveroK . Sertindole and haloperidol revisited; the psychometric triangle. Schizophrenia Research2010;117(2‐3):259. BeraRB , PotkinSG . [Brain imaging to determine the effects of sertindole in schizophrenic patients]. Proceedings of 4th International Conference Schizophrenia: Breaking down the Barriers; October 6‐9th; Vancouver BC, Canada. 1996. DanielD , TargumS , ZimbroffD , MackR , ZborowskiJ , MorrisD , et al. Efficacy, safety, and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients. Proceedings of 34th Annual Meeting of the American College of Neuropsychopharmacology; December 11‐15th; San Juan, Puerto Rico. 1995. GlickID , RamirezL , McCarthyBG , KohlbeckP . [Extrapyramidal symptom profile of sertindole]. Proceedings of 53rd Annual Convention and Scientific Program of the Society of Biological Psychiatry; May 27‐31st; Toronto, Canada. 1998. LarsonGK , MackRJ , ZborowskiJ , MorrisDD , SebreeTB , WallinBA . Three doses each of sertindole and haloperidol in schizophrenics. Proceedings of Xth World Congress of Psychiatry; August 23‐28th; Madrid, Spain. 1996. MackR , ZborowskiJ , MorrisD , SebreeT , WallinB . [Efficacy, safety and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients]. Proceedings of 34th Annual Meeting of the American College of Neuropsychopharmacology; December 11‐15th; San Juan, Puerto ‐Rico. 1995. PotkinSG , ZborowskiJ , JosephN , WuC , MackRJ , SebreeTB , et al. [Brain Imaging to determine the effects of sertindole in schizophrenic patients]. Proceedings of 149th Annual Meeting American Psychiatric Association; May 4‐9th. 1996. SchulzSC , MackR , ZborowskiJ , MorrisD , SebreeT , WallinB . [Efficacy, safety and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients]. Proceedings of 8th Biennial Winter Workshop on Schizophrenia, Crans Montana; March 16‐22nd; Switzerland. 1996. TammingaC , MackRJ , ZborowskiJG , MorrisD , SebreeB . Efficacy and safety of three doses of sertindole and haldol in schizophrenic patients. Proceedings of XXth Collegium Internationale Neuro‐Psychopharmacologicum; June 23‐27th; Melbourne, Australia. 1996. TammingaCA , MackRA , GrannemanGR , SilberCJ , KashkinKB . Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. International Clinical Psychopharmacology1997;12:S29‐35. TargumS , ZborowskiJ , SchmitzHM , SebreeT , WallinB . [Efficacy and safety of sertindole in two double‐blind, placebo‐controlled trials of schizophrenic patients]. Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress; September 30th ‐ October 4th; Venice, Italy. 1995. ZimbroffD , MackRJ , ZborowskiJG , MorrisDD . The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients. Proceeding of 149th American Psychiatric Association Annual Meeting; May 4‐9th. 1996. ZimbroffDL , KaneJM , TammingaCA . "Sertindole versus haloperidol for schizophrenia": Dr. Zimbroff and colleagues reply. American Journal of Psychiatry1998;155(9):1303‐4. ZimbroffDL , KaneJM , TammingaCA , DanielDG , MackRJ , WozniakPJ , et al. Sertindole Study Group. Controlled, dose‐response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry1997;154(6):782‐91. '>Zimbroff 1997</a> only reported the total number of losses, not per treatment group; <a href="./references#CD003082-bbs2-0045" title="BrowneFWA , CooperSJ , WilsonR , KingDJ . Serum haloperidol levels and clinical response in chronic, treatment resistant schizophrenic patients. Journal of Psychopharmacology1988;2:94‐103. ">Browne 1988</a> allowed people who had relapsed to re‐enter the study under single‐blind conditions; and <a href="./references#CD003082-bbs2-0099" title="AndersonC , TrueJ , EreshefskyL , MillerA . [Risperidone. Clinical efficacy: role of the metabolite 9‐hydroxy‐risperidone]. Proceedings of 33rd Annual Meeting of the New Clinical Drug Evaluation Unit. June 1‐4th; Boca Raton, USA. 1993. AndersonCB , TrueJ , MillerAL , PetersB , VelliganDI . [Risperidone dose, plasma levels and response]. Proceedings of 146th Annual Meeting of the American Psychiatric Association. May 22‐27th; San Fransico, USA. 1993. LindenmayerJP . [Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia]. Proceedings of 146th Meeting of the American Psychiatric Association. May 22‐27th; San Fransico, USA. 1993. MarderS . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS‐INT‐31991. MarderSR . [Risperidone: Clinical development: North American Results]. Proceedings of 18th Collegium Internationale Neuropsychopharmacologicum Congress; June 28th ‐ July 2nd; Nice, France. 1992. MarderSR . [Risperidone: efficacy on positive and negative symptoms]. Proceedings of 1st International Risperidone Investigators Meeting; March 9‐10th; Paris, France. 1992. MarderSR . [Risperidone: Efficacy]. Proceedings of a roundtable meeting: Update on Serotonin/Dopamine Antagonists in Psychiatry; January 7th; New Orleans, USA. 1994. MarderSR . Risperidone: Clinical development: North American Results. Clinical Neuropharmacology1992;15(1):S92‐3. MarderSR , ChouinardG , DavisJM . [The clinical actions of risperidone]. Proceedings of 10th Congress of the European College of Neuropsychopharmacology; September 13‐17th; Vienna, Austria. 1997. MarderSR , ChouinardG , DavisJM . [The clinical actions of risperidone]. Proceedings of 35th Annual Meeting of the American College of Neuropsychopharmacology; December 9‐13th; San Juan, Puerto Rico. 1996. MarderSR , ChouinardG , DavisJM . [The clinical actions of risperidone]. Proceedings of 6th World Congress of Biological Psychiatry; June 22‐27th; Nice, France. 1997. MarderSR , DavisJM , ChouinardG . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychiatry1997;58:538‐46. McEvoyJP . Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry1994;55(5):S18‐21. MeibachRC , Risperidone Study Group. [A fixed‐dose, parallel group study of risperidone vs haloperidol vs placebo]. Proceedings of 4th International Congress on Schizophrenia Research; April 17‐21st; Colorado Springs, USA. 1993. MollerHJ . [Incidence of EPS under risperidone therapy]. Proceedings of 1st International Risperidone Investigators Meeting; March 9‐10th; Paris, France. 1992. SchoolerNR . [Negative symptoms, risperidone and dose]. Proceedings of 146th American Psychiatric Association Annual Meeting; May 22‐27th; San Fransico, USA. 1993. SchoolerNR . Negative symptoms in schizophrenia:assessment of the effect of risperidone. Journal of Clinical Psychiatry1994;55(5):S22‐8. SimpsonGM , LindenmayerJP . Extrapyramidal Symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology1997;17:194‐201. ">North America 1997</a> combines data from several centres, which combined has greater than 50% loss, instead data from publications of specific centres have been included (<a href="./references#CD003082-bbs2-0006" title="ChouinardG . Effects of risperidone in tardive dyskinesia: An analysis of the Canadian multicentre risperidone study. Journal of Clinical Psychopharmacology1995;15:S36‐44. ChouinardG , AlbrightP . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17:298‐307. ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Proceedings 47th Annual Convention and Scientific Program of the Society of Biological Psychiatry. April 29th ‐ May 3rd; Washington DC, USA. 1992. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian Multicentre placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13:25‐40. ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. Proceedings of 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress. June 27th ‐ July 1st; Washington DC, USA. 1994. ChouindardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Proceedings of 18th Collegium Internationale Neuro‐Psychopharmacologicum Congress. June 28th ‐ July 2nd; Nice, France. 1992. NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. http://www.clinicaltrials.gov2005. ">Chouinard 1993</a>; <a href="./references#CD003082-bbs2-0015" title="MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151:825‐35. ">Marder 1994</a>). The other six either reported data incorrectly. We had to exclude <a href="./references#CD003082-bbs2-0106" title="PoolD , BloomW , MielkerDH , RonigerJJ , GallantDM . A controlled evaluation of loxitane in seventy‐five adolescent schizophrenic patients. Current Therapeutic Research1976;19:99‐104. ">Pool 1976</a> and <a href="./references#CD003082-bbs2-0111" title="PriceWA . Antipsychotic effects of Verapamil in schizophrenia. Hillside Journal of Clinical Psychiatry1987;9:225‐30. ">Price 1987</a> because they replaced people who withdrew from the trial with people whom they did not randomise and presented outcomes that included data from these non‐random additions. </p> </section> </section> <section id="CD003082-sec-0116"> <h3 class="title">Risk of bias in included studies</h3> <p>See also 'Risk of bias' tables in <a href="./references#CD003082-sec-0198" title="">Characteristics of included studies</a>, and <a href="#CD003082-fig-0002">Figure 2</a> and <a href="#CD003082-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD003082-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003082-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003082-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003082-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003082-sec-0117"> <h4 class="title">Allocation</h4> <p>All included studies were reported as randomised. A few studies mentioned the use of 'randomised blind schedules' (<a href="./references#CD003082-bbs2-0004" title="BorisonRL , SinahD , HaverstockS , McLarnonMC , DiamondB . Efficacy and safety of tiospirone vs haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989;25:190‐3. ">Borison 1989</a>; <a href="./references#CD003082-bbs2-0014" title="KlieserE , LehmannE . Experimental examination of trazodone. Clinical Neuropharmacology1989;12:S18‐24. ">Klieser 1989</a>) and/or patient codes (<a href="./references#CD003082-bbs2-0003" title="BechelliLPC , Ruffino‐NettoA , HetemG . A double‐blind controlled trial of pipotiazine, haloperidol and placebo in recently hospitalised acute schizophrenic patients. Brazilian Journal of Biological Research1983;16:305‐11. ">Bechelli 1983</a>; <a href="./references#CD003082-bbs2-0024" title="SpencerE , AlpertM , PougetE . Scales for the assessment of neuroleptic response in schizophrenic children: Specific measures derived from the CPRS. Psychopharmacology Bulletin1994;30:199‐202. SpencerEK , AlpertM , PougetER . [Two sensitive and specific scales derived from the CPRS for assessing haloperidol response in hospitalised schizophrenic children]. Proceedings of 33rd Annual Meeting of the New Clinical Drug Evaluation Unit. June 1‐4th; Boca Raton, USA. 1993. SpencerEK , KafantarisV , Padron‐GayolMV , RosenbergCR , CampbellM . Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacology Bulletin1992;28:183‐6. ">Spencer 1992</a>; <a href="./references#CD003082-bbs2-0023" title="SimpsonGM , AngusJWS , EdwardsJG . A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research1967;9:407‐12. ">Simpson 1967</a>) but it was not stated how these were generated or used. We therefore categorised these studies as unclear risk of bias. Only two studies reported method of generation of randomisation sequence and were rated low risk of bias (<a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a> and <a href="./references#CD003082-bbs2-0009" title="GarryJW , LeonardTJ . Haloperidol: A controlled trial in chronic schizophrenia. British Journal of Psychiatry1962;108:105‐7. ">Garry 1962</a>). </p> <p>Only one study (<a href="./references#CD003082-bbs2-0009" title="GarryJW , LeonardTJ . Haloperidol: A controlled trial in chronic schizophrenia. British Journal of Psychiatry1962;108:105‐7. ">Garry 1962</a>) reported method of allocation concealment and was rated low risk of bias, whereas the other studies did not provide any details and were rated unclear risk of bias for allocation concealment. </p> </section> <section id="CD003082-sec-0118"> <h4 class="title">Blinding</h4> <p>All studies were reported to be double‐blind although this was difficult to maintain due to the appearance of characteristic adverse side effects when administering haloperidol. Some trials tried to overcome this by masking some of the side effects with antiparkinson medication. Nine studies were rated low risk of bias for blinding of participants and personnel, most of these specifically stated blindness was achieved through use of identical capsules and/or bottles of medication (<a href="./references#CD003082-bbs2-0006" title="ChouinardG . Effects of risperidone in tardive dyskinesia: An analysis of the Canadian multicentre risperidone study. Journal of Clinical Psychopharmacology1995;15:S36‐44. ChouinardG , AlbrightP . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17:298‐307. ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Proceedings 47th Annual Convention and Scientific Program of the Society of Biological Psychiatry. April 29th ‐ May 3rd; Washington DC, USA. 1992. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian Multicentre placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13:25‐40. ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. Proceedings of 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress. June 27th ‐ July 1st; Washington DC, USA. 1994. ChouindardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Proceedings of 18th Collegium Internationale Neuro‐Psychopharmacologicum Congress. June 28th ‐ July 2nd; Nice, France. 1992. NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. http://www.clinicaltrials.gov2005. ">Chouinard 1993</a>, <a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a>, <a href="./references#CD003082-bbs2-0010" title="HowardJ . Haloperidol for chronically hospitalised psychotics: A double‐blind comparison with thiothixene and placebo; a follow‐up open evaluation. Diseases of the Nervous System1974;35:458‐63. ">Howard 1974</a>, <a href="./references#CD003082-bbs2-0011" title="JannMW , CrabtreeBL , PittsWM , Francis LamYW , CarterJG . Plasma alpha‐one acid glycoprotein and haloperidol concentrations in schizophrenic patients. Neuropsychobiology1997;36:32‐6. ">Jann 1997</a>, <a href="./references#CD003082-bbs2-0018" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics. Psychopharmacology1982;77:301‐4. ">Nishikawa 1982</a>, <a href="./references#CD003082-bbs2-0019" title="NishikawaT , TsudaA , TanakaM , HoakiY , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics: A comparative dose‐response study of haloperidol and propericiazine. Psychopharmacology1984;82:153‐6. ">Nishikawa 1984</a>, <a href="./references#CD003082-bbs2-0022" title="SefafetinidesEA , WillisD , ClarkML . Haloperidol, Clopenthixol and Chlorpromazine in chronic schizophrenia: II The electroencephalographic effects of chemically unrelated antipsychotics. Journal of Nervous and Mental Disease1972;155:366‐9. SerafentinidesEA . Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry1973;8:214‐6. SerafetinidesEA . Voltage laterality in the EEG of psychiatric patients. Diseases of the Nervous System1973;34:190‐1. SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973;7:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, Clopenthixol and Chlorpromazine in chronic schizophrenia: Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972;154:31‐42. ">Serafetinides 1972</a>, <a href="./references#CD003082-bbs2-0021" title="SelmanFB , McClureRF , HelwigH . Loxapine succinate: A double‐blind comparison with haloperidol and placebo in acute schizophrenics. Current Therapeutic Research1976;19:645‐52. SelmanFB , McClureRF , HelwigH . Loxapine succinate: essai comparatif en double aveugle avec l'haloperidol et un placebo dans les psychoses aigues. Psychololgie Medicale1979;11:1533‐40. ">Selman 1976</a>), but no trial tested whether their attempts at blinding had been successful. Only four studies described outcome assessors as being blinded to treatment and were rated low risk of bias (<a href="./references#CD003082-bbs2-0003" title="BechelliLPC , Ruffino‐NettoA , HetemG . A double‐blind controlled trial of pipotiazine, haloperidol and placebo in recently hospitalised acute schizophrenic patients. Brazilian Journal of Biological Research1983;16:305‐11. ">Bechelli 1983</a>, <a href="./references#CD003082-bbs2-0007" title="DurostH , LeeH , ArthursD . An early evaluation of Haloperidol. The Butyrophenones in Psychiatry. Edited by HE Lehmann and TA Ban. Channel Press Inc, 1964:70‐3. ">Durost 1964</a>, <a href="./references#CD003082-bbs2-0012" title="AnutoshS , AliMW , IngenitoG , CarsonWH . Controlled study of aripiprazole and haloperidol in schizophrenia. 11th Association of European Psychiatrists Congress. May 4‐8, Stockholm, Sweden. 2002. CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 13th Congress of the European College of Neuropsychopharmacology [CD‐ROM]: Conifer Excerpta Medica Medical Communications BV. P2075. 2000. DanielD , StockE , WilberC , MarcusR , CarsonWHJr , ManosG , et al. Intramuscular Aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association. May 1‐6; New York, USA. 2004. KaneJM , CarsonWH , SahaAR , McQuadeRD , IngenitoGG , ZimbroffDL , et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry2002;63(9):763‐71. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychoitc disorders: comparison with haloperidol and placebo. 153rd Annual Meeting of the American Psychiatric Association. May 13‐8; Chicago, USA. 2000. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 155th Annual Meeting of the American Psychiatric Association. May 18‐23; Philadelphia, PA, USA. 2002. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Abstracts of the XII CINP Congress, Brussels, Belgium, July 9‐13. 2000. ">Kane 2002</a> and <a href="./references#CD003082-bbs2-0021" title="SelmanFB , McClureRF , HelwigH . Loxapine succinate: A double‐blind comparison with haloperidol and placebo in acute schizophrenics. Current Therapeutic Research1976;19:645‐52. SelmanFB , McClureRF , HelwigH . Loxapine succinate: essai comparatif en double aveugle avec l'haloperidol et un placebo dans les psychoses aigues. Psychololgie Medicale1979;11:1533‐40. ">Selman 1976</a>). The remaining studies were of unclear risk of bias as no information on blinding of outcome assessors was provided. </p> </section> <section id="CD003082-sec-0119"> <h4 class="title">Incomplete outcome data</h4> <p>Ten studies were rated as low risk of bias for incomplete outcome data and six studies had an unclear risk of bias. Nine studies were rated as high risk of bias, for seven of these it was due to more than 50% of losses to follow‐up (<a href="./references#CD003082-bbs2-0001" title="ArvanitisLA , MillerBG . (ICI 204,636): An atypical antipsychotic: Results from a multiple fixed dose, placebo‐controlled study. Proceedings of XXth Collegium Internationale Neuro‐Psychopharmacologicum. June 23‐27th; Melbourne, Australia. 1996. ArvanitisLA , MillerBG . Quetiapine, an atypical antipsychotic ‐ results from a multiple fixed dose, placebo‐controlled study. Proceedings of 149th Annual Meeting American Psychiatric Association. May 4‐9th. 1996. ArvanitisLA , MillerBG , KowalcykBB . Efficacy of 'Seroquel' (Quetiapine Fumarate) in affective symptoms of schizophrenia). Proceedings of 36th Annual Meeting of the American College of Neuropsychopharmacology. December 8‐12th; Waikoloa, Hawai, USA. 1997. ArvanitisLA , MillerBG , Seroquel Trial 13 Study Group. Multiple fixed doses of &quot;Seroquel&quot; (Quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biological Psychiatry1997;42:233‐46. BorisonRL , ArvanitisLA , MillerBG . A comparison of five fixed doese of 'Seroquel' (ICI 204,636) with haloperidol and placebo in patients with schizophrenia. Proceedings of 8th Biennial Winter Workshop on Schizophrenia. March 16‐22nd; Crans Montana, Switzerland. 1996. BorisonRL , ArvantisLA , MillerBG . A multiple fixed‐dose, placebo‐controlled trial with 'Seroquel' ‐ An atypical antipsychotic. Biological Psychiatry1996;39:333. CantillonM . [Quetiapine fumarate reduces aggression]. Proceedings of the 11th Annual Meeting of the American Association of Geriatric Psychiatry; San Diego, California, USA. 1997. CantillonM , ArvanitisLA , MillerBG , Kowalcyk . 'Seroquel' (Quetiapine Fumarate) reduces hostility and aggression in patients with acute schizophrenia. Proceedings of 36th Annual Meeting of the American College of Neuropsychopharmacology. December 8‐12th; Waikoloa, Hawai, USA. 1997. CantillonM , GoldsteinJM . Efficacy of Quetiapine fumarate in affective symptoms of schizophrenia. Proceedings of American Psychiatric Association Annual Meeting. May 30th‐June 4th; Toronto, Ontario, Canada. 1998. HellewellJSE , Cameron‐HandsD , CantillonM . Seroquel: Evidence for efficacy in the treatment of hostility and aggression. 9th Biennial Winter Workshop on Schizophrenia. February 7‐13th; Davos, Switzerland. 1998. HongW , ArvanitisL . Reduction of the positive symptoms of schizophrenia by (ICI 204,636): Results from phase II and III clinical trials. Proceedings of 9th European College of Neuropsychopharmacology Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. HongWW , ArvanitisL . The atypical profile of (ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic patients. Proceedings of the 9th European College of Neuropsychopharmacology Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. HongWW , ArvanitisLA , MillerBG . (ICI 204,636) does not differ from placebo in the incidence of EPS or effect on plasma prolactin. Proceedings of the XXth Collegium Internationale Neuro‐psychopharmacologicum. June 23‐27th; Melbourne, Australia. 1996. HongWW , ArvanitisLA , MillerBG . Quetiapine does not differ from placebo in the incidence of extrapyramidal syndrome of effect on plasma prolactin. Proceedings of the 149th Annual Meeting American Psychiatric Association. May 4‐9th. 1996. ">Arvanitis 1997</a>; <a href="./references#CD003082-bbs2-0002" title="Ascher‐SvanumH , StenslandMD , KinonBJ , TollefsonGD . Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. Journal of Psychopharmacology2005;19(6 Suppl):110‐7. [MEDLINE: 16280344] BeasleyC , TollefsonGD , BeuzenJN , DellvaMA , SangerTM , PaulS . Acute and long‐term results of the North American double‐blind olanzapine trial. Proceedings of the 4th International Conference. October 6‐9th; Vancouver BC, Canada. 1996. BeasleyCM , TollefsonG , TranP , SatterleeW , SangerT , HamiltonS , Olanzapine HGAD study group. Olanzapine versus placebo and haloperidol; Acute phase results of the North American double‐blind olanzapine trial. Neuropsychopharmacology1996;14:111‐23. BeasleyCM , TollefsonGD , TranPV . Efficacy of Olanzapine: An overview of pivotal clinical trials. Journal of Clinical Psychiatry1997;58:7‐12. CrawfordAMK , BeasleyCM , TollefsonGD . The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research1997;26:41‐54. HamiltonSH , RevickiDA , GendusoLA , BeasleyCM . Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double‐blind trial. Neuropsychopharmacology1998;18:41‐9. PerryPJ , LundBC , SangerT , BeasleyC . Olanzapine plasma concentrations and clinical response: Acute phase results of the North American Olanzapine trial. Journal of Clinical Psychopharmacology2001;21:14‐20. RevickiD , GendusoL . Effect of Olanzapine on deficit syndrome symptoms in chronic schizophrenia. Proceedings of 8th ECNP (European College of Neuropsychopharmacology) Congress; September 30th ‐ October 4th; Venice, Italy. 1997. SangerT , TollefsonGD . A controlled study on the course of primary and secondary negative symptoms. Proceedings of 150th American Psychiatric Association Annual Meeting. San Diego, USA. 1997. SatterleeW , BeasleyC , SangerT , TranP , TollefsonG . Olanzapine, a new atypical antipsychotic. Proceedings of 5th International Congress on Schizophrenia Research. April 6‐12th; Wormsprings, USA. 1996. TollefsonG . Update on new atypical antipsychotics. Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress. September 30th ‐ October 4th; Venice, Italy. 1995. TollefsonG , BeasleyC , TranP , SangerT . Olanzapine: An exciting atypical antipsychotic. The clinical experience. Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress. September 30th ‐ October 4th; Venice, Italy. 1995. TollefsonG , SangerT , BeasleyC . The course of primary and secondary negative symptoms in a placebo‐and comparator‐controlled trial of the typical antipsychotic olanzapine. Proceedings of 9th ECNP (European College of Neuropsychopharmacology) Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. TollefsonGD . Olanzapine: A novel antipsychotic with a broad spectrum profile. Proceedings of XIXth Collegium Internationale Neuro‐psychopharmacologicum Congress. June 27th ‐ July 1st; Washington DC, USA. 1994. TollefsonGD . The value of atypical antipsychotic medications. Proceedings of 150th American Psychiatric Association Annual Meeting. San Diego, USA. 1997. TollefsonGD , BeasleyCM , TranPV , SangerT . [The next generation of antipsychotics]. Proceedings of 148th Annual Meeting of the American Psychiatric Association. May 20‐5th; Miami, USA. 1995. TollefsonGD , BeasleyCM , TranPV , SangerT . Olanzapine: A novel antipsychotic with a broad spectrum. Proceedings of 49th Annual Convention and Scientific Program of the Society of Biological Psychiatry. May 18‐22nd; Philadelphia, USA. 1994. TollefsonGD , SangerT , BeasleyCM . The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Proceedings of 149th American Psychiatric Association Annual Meeting. May 4‐9th. 1996. TollefsonGD , SangerTM . Negative symptoms: A path analytic approach to a double‐blind, placebo and haloperidol controlled clinical trial with olanzapine. American Journal of Psychiatry1997;154:466‐74. TollefsonGD , SangerTM , BeasleyCM . The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Proceedings of XXth Collegium Internationale Neuro‐psychopharmacologicum. June 23‐27th; Melbourne, Australia. 1996. TollefsonGD , SangerTM , BeasleyCM , TranPV . A double‐blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological Psychiatry1998;43:803‐10. TollefsonGD , SangerTM , BeasleyCM , TranPV . Is there a relationship between EPSE and efficacy: faction or fiction. Proceedings of Campaign on Schizophrenia. March 10‐12th; Florence, Italy. 1995. TranP , BeasleyC , TollefsonG , BeuzenJ , DellvaM , SangerT , eral . Acute and long‐term results of the North American double‐blind Olanzapine trial. Proceedings of 8th ECNP (European College of Neuropsychopharmacology) Congress. September 30th ‐ October 4th; Venice, Italy. 1995. TranP , BeasleyC , TollefsonG , DellvaM , HamiltonS , VanOstrandR , et al. Acute and long term results of the North American double‐blind olanzapine trial. Proceedings of 20th Collegium Internationale Neuropsychopharmacologicum Congress. June 23‐27th; Melbourne, Australia. 1996. TranP , DellvaM , RampeyV , TollefsonG , BeasleyC . Long‐term continuation therapy with the novel antipsychotic olanzapine: A review of the clinical experience. Proceedings of 9th ECNP (European College of Neuropsychopharmacology) Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. TranPV , BeasleyCM , TollefsonGD , SangerT , SatterleeWG . Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent. Proceedings of XIXth Collegium Internationale Neuro‐psychopharmacologicum Congress. June 27th ‐ July 1st; Washington DC, USA. 1994. WoodAJ , BeasleyCM , TollefsonGD , TranPV . [Efficacy of olanzapine in the post ive and negative symptoms of schizophrenia]. Proceedings of 7th Congress of the European College of Neuropsychopharmacology. October 16‐21st; Jerusalem, Israel. 1994. ">Beasley 1996</a>; <a href="./references#CD003082-bbs2-0006" title="ChouinardG . Effects of risperidone in tardive dyskinesia: An analysis of the Canadian multicentre risperidone study. Journal of Clinical Psychopharmacology1995;15:S36‐44. ChouinardG , AlbrightP . Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology1997;17:298‐307. ChouinardG , ArnottW . The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Proceedings 47th Annual Convention and Scientific Program of the Society of Biological Psychiatry. April 29th ‐ May 3rd; Washington DC, USA. 1992. ChouinardG , JonesB , RemingtonG , BloomD , AddingtonD , MacEwanGW , et al. A Canadian Multicentre placebo‐controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology1993;13:25‐40. ChouinardG , VainerJL , BeauclairL . Dose regimens of neuroleptics in negative symptoms. Proceedings of 19th Collegium Internationale Neuro‐Psychopharmacologicum Congress. June 27th ‐ July 1st; Washington DC, USA. 1994. ChouindardG , ArnottW . Antidyskinetic effect of risperidone in chronic schizophrenic patients. Proceedings of 18th Collegium Internationale Neuro‐Psychopharmacologicum Congress. June 28th ‐ July 2nd; Nice, France. 1992. NCT00249132 . Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. http://www.clinicaltrials.gov2005. ">Chouinard 1993</a>; <a href="./references#CD003082-bbs2-0015" title="MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151:825‐35. ">Marder 1994</a>; <a href="./references#CD003082-bbs2-0016" title="MeltzerHY . Testing multiple novel mechanisms for treating schizophrenia in a single trial. In: CummingsJL editor(s). Progress in Neurotherapeutics and Neuropsychopharmacology. New York, NY, US: Cambridge University Press, 2006:115‐20. Meltzer , HY , ArvanitisL , BauerD , Rein W and Meta‐trial Study Group. Placebo‐controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. American Journal of Psychiatry2004;161(6):975‐84. ">Meltzer 2004</a>; <a href="./references#CD003082-bbs2-0017" title="NCT00044044 . A 6‐week, double‐blind, randomized, fixed‐dose, parallel‐group study of the efficacy and safety of three dose levels of SM‐13496 compared to placebo and haloperidol in patients with schizophrenia who are experiencing an acute exacerbation of symptoms. www.ClinicalTrials.gov (accessed on 30 Oct 2012).2002. ">NCT00044044 2002</a>; <a href="./references#CD003082-bbs2-0020" title="PotkinSG , LitmanRE , TorresR , WolfgangCD . Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. Journal of Clinical Psychopharmacology2008;28(2 Suppl 1):S4‐S11. ">Potkin 2008</a>). For these studies only the outcome 'Leaving the study early' was collected for the review, see <a href="#CD003082-sec-0073">Dealing with missing data</a>. </p> </section> <section id="CD003082-sec-0120"> <h4 class="title">Selective reporting</h4> <p>Six studies were of low risk of bias with regard to selective reporting, and two were unclear. The remaining 17 studies were of high risk of bias, mainly due to poor data reporting. Overall, there were very little data that were possible to use from the 25 included trials. Continuous data were particularly problematic. Many studies presented findings without standard deviations or any other measure of variance, in graphs, in percentiles or by inexact P values. 'P' values are commonly used as a measure of association between intervention and outcomes instead of showing the strength of the association. Further, many pre‐planned outcomes were not reported at all. </p> </section> <section id="CD003082-sec-0121"> <h4 class="title">Other potential sources of bias</h4> <p>Eleven trials were subject to other biases as they were either partly or fully funded by the pharmaceutical industry. Only one study was of low risk of bias for other potential sources of bias (<a href="./references#CD003082-bbs2-0022" title="SefafetinidesEA , WillisD , ClarkML . Haloperidol, Clopenthixol and Chlorpromazine in chronic schizophrenia: II The electroencephalographic effects of chemically unrelated antipsychotics. Journal of Nervous and Mental Disease1972;155:366‐9. SerafentinidesEA . Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry1973;8:214‐6. SerafetinidesEA . Voltage laterality in the EEG of psychiatric patients. Diseases of the Nervous System1973;34:190‐1. SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973;7:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, Clopenthixol and Chlorpromazine in chronic schizophrenia: Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972;154:31‐42. ">Serafetinides 1972</a>) and the remaining 13 had an unclear risk of bias, three of which had the drugs used in the trials provided by the pharmaceutical industry. </p> </section> </section> <section id="CD003082-sec-0122"> <h3 class="title" id="CD003082-sec-0122">Effects of interventions</h3> <p>See: <a href="./full#CD003082-tbl-0001"><b>Summary of findings for the main comparison</b> HALOPERIDOL versus PLACEBO for schizophrenia</a> </p> <section id="CD003082-sec-0123"> <h4 class="title">1. Comparison: HALOPERIDOL versus PLACEBO</h4> <p>We grouped outcomes as immediate (up to six weeks), short (six weeks to six months), medium (six months to one year) and long term (over one year). We used risk ratios (RR) for dichotomous data and mean differences (MD) for continuous data, with their respective 95% confidence intervals (CIs) throughout. </p> <section id="CD003082-sec-0124"> <h5 class="title">1.1 Death – suicide or natural causes</h5> <p>None of the 25 included studies reported on this outcome.</p> </section> <section id="CD003082-sec-0125"> <h5 class="title">1.2 Global state</h5> <section id="CD003082-sec-0126"> <h6 class="title">1.2.1 Overall improvement</h6> <p>Results favoured haloperidol (<a href="./references#CD003082-fig-0004" title="">Analysis 1.1</a>). Four trials found that a marked improvement was significantly more likely at up to six weeks with haloperidol (n = 472, RR 0.67 CI 0.56 to 0.80) compared with placebo. Results were heterogenous (I<sup>2</sup> = 72%); when the data are analysed using random‐effects, the result remains significant (RR 0.59 CI 0.39 to 0.89). This heterogeneity is explored in the results of subgroup analyses (<a href="./references#CD003082-fig-0024" title="">Analysis 1.21</a>; <a href="./references#CD003082-fig-0025" title="">Analysis 1.22</a>), and in sensitivity analysis (<a href="./references#CD003082-fig-0026" title="">Analysis 1.23</a>). We found, when splitting the studies by low dose and medium to high dose, the heterogeneity was removed (see subgroup analysis section 2.4, <a href="./references#CD003082-fig-0024" title="">Analysis 1.21</a>). </p> <p>A further eight trials also found a significant difference favouring haloperidol across the six weeks to six months period (n = 307, RR 0.67 CI 0.58 to 0.78). <a href="./references#CD003082-bbs2-0022" title="SefafetinidesEA , WillisD , ClarkML . Haloperidol, Clopenthixol and Chlorpromazine in chronic schizophrenia: II The electroencephalographic effects of chemically unrelated antipsychotics. Journal of Nervous and Mental Disease1972;155:366‐9. SerafentinidesEA . Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry1973;8:214‐6. SerafetinidesEA . Voltage laterality in the EEG of psychiatric patients. Diseases of the Nervous System1973;34:190‐1. SerafetinidesEA , ClarkML . Psychological effects of single dose antipsychotic medication. Biological Psychiatry1973;7:263‐7. SerafetinidesEA , CollinsS , ClarkML . Haloperidol, Clopenthixol and Chlorpromazine in chronic schizophrenia: Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease1972;154:31‐42. ">Serafetinides 1972</a> reported results for 'nurse‐rated' global improvement across this time period, as opposed to the other 'clinician‐rated' trials, and found similar results favouring haloperidol (n = 28, RR 0.59 CI 0.37 to 0.92). </p> <p><a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a> and <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a> reported average change at six weeks on the CGI‐S scale (<a href="./references#CD003082-fig-0005" title="">Analysis 1.2</a>). Results favoured haloperidol (n = 353, MD ‐0.49 CI ‐0.73 to ‐0.25). </p> </section> <section id="CD003082-sec-0127"> <h6 class="title">1.2.2 Hospital discharge</h6> <p>Only one study, <a href="./references#CD003082-bbs2-0010" title="HowardJ . Haloperidol for chronically hospitalised psychotics: A double‐blind comparison with thiothixene and placebo; a follow‐up open evaluation. Diseases of the Nervous System1974;35:458‐63. ">Howard 1974</a> reported usable data on hospitalisation‐related outcomes. This small trial found no difference between haloperidol and placebo for not being discharged from hospital between six weeks and six months (1 RCT n = 33; <a href="./references#CD003082-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD003082-sec-0128"> <h6 class="title">1.2.3 Relapse</h6> <p>Only two studies reported on relapse. <a href="./references#CD003082-bbs2-0018" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics. Psychopharmacology1982;77:301‐4. ">Nishikawa 1982</a> and <a href="./references#CD003082-bbs2-0019" title="NishikawaT , TsudaA , TanakaM , HoakiY , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics: A comparative dose‐response study of haloperidol and propericiazine. Psychopharmacology1984;82:153‐6. ">Nishikawa 1984</a> found that once a person's illness was stable and in remission, if haloperidol was started, it was more likely to keep people in remission than placebo (n = 70, RR 0.69 CI 0.55 to 0.86; <a href="./references#CD003082-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD003082-sec-0129"> <h6 class="title">1.2.4 Leaving the study early</h6> <p>Sixteen studies with up to six weeks follow‐up, found that people allocated to haloperidol were more likely to remain in the study than participants receiving placebo (n = 1812, RR 0.87 CI 0.80 to 0.95). At six weeks to six months follow‐up, results were equivocal (8 RCTs n = 304), as they were for <a href="./references#CD003082-bbs2-0019" title="NishikawaT , TsudaA , TanakaM , HoakiY , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics: A comparative dose‐response study of haloperidol and propericiazine. Psychopharmacology1984;82:153‐6. ">Nishikawa 1984</a> at one year follow‐up (n = 50; <a href="./references#CD003082-fig-0008" title="">Analysis 1.5</a>). </p> <p>We did not identify any studies reporting on re‐admission or satisfaction with treatment.</p> </section> </section> <section id="CD003082-sec-0130"> <h5 class="title">1.3 Mental state</h5> <p>Only six studies had useable data on mental state outcomes.</p> <section id="CD003082-sec-0131"> <h6 class="title">1.3.1 Overall improvement</h6> <p>No significant difference was found at up to six weeks follow‐up by <a href="./references#CD003082-bbs2-0005" title="BorisonR , PathiragaA , DiamondB , MeibachR . Risperidone and Schizophrenia. Proceedings of 5th World Congress of Biological Psychiatry. June 9‐14th; Florence, Italy. 1991. BorisonRL , DiamondBI , AugustaGA . Serotonin modulation of dopaminergic‐medicated extrapyramidal side effects. Proceedings of 43rd Annual Meeting of the American Academy of Neurology. April 21‐27th; Boston, USA. 1991. BorisonRL , DiamondBI , PathirajaA , MeibachRC . Clinical profile of risperidone in chronic schizophrenia. Proceedings of 17th Congress of Collegium Internationale Neuro‐psychopharmacologicum. 1993. BorisonRL , PathirajaAP , DiamondB , MeibachRC . Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin1992;28:213‐8. ">Borison 1992a</a> when measuring clinical improvement by reduction in BPRS scores by at least 20% (n = 24; <a href="./references#CD003082-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD003082-sec-0132"> <h6 class="title">1.3.2 General symptoms</h6> <p>The result from three studies showed a significant difference favouring haloperidol for the average BPRS score at six weeks (n = 108, MD ‐9.76 CI ‐14.60 to ‐4.93; <a href="./references#CD003082-fig-0010" title="">Analysis 1.7</a>), but with significant heterogeneity (I<sup>2</sup> = 81.9). Removing the study with results that were causing this heterogeneity, as judged by visual inspection (<a href="./references#CD003082-bbs2-0014" title="KlieserE , LehmannE . Experimental examination of trazodone. Clinical Neuropharmacology1989;12:S18‐24. ">Klieser 1989</a>, which reported average change data, whereas the other two studies, <a href="./references#CD003082-bbs2-0003" title="BechelliLPC , Ruffino‐NettoA , HetemG . A double‐blind controlled trial of pipotiazine, haloperidol and placebo in recently hospitalised acute schizophrenic patients. Brazilian Journal of Biological Research1983;16:305‐11. ">Bechelli 1983</a> and <a href="./references#CD003082-bbs2-0011" title="JannMW , CrabtreeBL , PittsWM , Francis LamYW , CarterJG . Plasma alpha‐one acid glycoprotein and haloperidol concentrations in schizophrenic patients. Neuropsychobiology1997;36:32‐6. ">Jann 1997</a>, reported average and point data), eliminates this heterogeneity. However, it is unclear what the reason for heterogeneity is because there are only three, small studies included. Finally, for average change at six weeks on the PANSS total scale, data from <a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a> favoured haloperidol (n = 119, MD ‐15.58 CI ‐23.92 to ‐7.24; <a href="./references#CD003082-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD003082-sec-0133"> <h6 class="title">1.3.3 Positive symptoms</h6> <p><a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a> and <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a> found an improvement in symptoms favouring haloperidol on the PANSS positive scale average change scores at six weeks (n = 353, MD ‐3.29 CI ‐4.70 to ‐1.89; <a href="./references#CD003082-fig-0012" title="">Analysis 1.9</a>). Results were heterogenous (I<sup>2</sup> = 83%) and there was no obviously outlying study out of the two. When the results are analyses using random‐effects, the results remain significant (MD ‐3.97 CI ‐7.72 to ‐0.23). </p> </section> <section id="CD003082-sec-0134"> <h6 class="title">1.3.4 Negative symptoms</h6> <p>Similarly, the same two studies found an improvement in symptoms on the PANSS negative scale average change scores at six weeks favouring haloperidol (n = 353, MD ‐1.18 CI ‐2.32 to ‐0.04; <a href="./references#CD003082-fig-0013" title="">Analysis 1.10</a>). </p> </section> <section id="CD003082-sec-0135"> <h6 class="title">1.3.5 Mood</h6> <p><a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a> found no significant difference for depression between haloperidol and placebo on the CDS average change scores (n = 234; <a href="./references#CD003082-fig-0014" title="">Analysis 1.11</a>). </p> </section> </section> <section id="CD003082-sec-0136"> <h5 class="title">1.4 Behaviour</h5> <p>None of the 25 included studies reported on behaviour outcomes such as social functioning, employment status or violent incidents. </p> </section> <section id="CD003082-sec-0137"> <h5 class="title">1.5 Adverse effects</h5> <section id="CD003082-sec-0138"> <h6 class="title">1.5.1 Movement disorders</h6> <p>Haloperidol causes various extrapyramidal adverse effects (<a href="./references#CD003082-fig-0015" title="">Analysis 1.12</a>), such as akathisia (6 RCTs n = 695, RR 3.66 CI 2.24 to 5.97), dystonia (5 RCT n = 471, RR 11.49 CI 3.23 to 40.85), parkinsonism (5 RCTs n = 485, RR 5.48 CI 2.68 to 11.22), rigidity (5 RCTs n = 461, RR 4.98 CI 2.74 to 9.05), and tremor (5 RCTs n = 447, RR 3.93 CI 1.96 to 7.91). Further, haloperidol increases the need for anti‐Parkinson medication (4 RCTs n = 480, RR 3.23 CI 2.20 to 4.72). However, data from the small study <a href="./references#CD003082-bbs2-0021" title="SelmanFB , McClureRF , HelwigH . Loxapine succinate: A double‐blind comparison with haloperidol and placebo in acute schizophrenics. Current Therapeutic Research1976;19:645‐52. SelmanFB , McClureRF , HelwigH . Loxapine succinate: essai comparatif en double aveugle avec l'haloperidol et un placebo dans les psychoses aigues. Psychololgie Medicale1979;11:1533‐40. ">Selman 1976</a> (n = 33) found no difference between placebo and haloperidol groups for teeth grinding or 'thick' speech. A further two studies found no difference for oculogyric crises (2 RCTs n = 83). </p> <p><a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a> and <a href="./references#CD003082-bbs2-0010" title="HowardJ . Haloperidol for chronically hospitalised psychotics: A double‐blind comparison with thiothixene and placebo; a follow‐up open evaluation. Diseases of the Nervous System1974;35:458‐63. ">Howard 1974</a> found no evidence that haloperidol causes tardive dyskinesia or dyskinesia (2 RCTs n = 157; <a href="./references#CD003082-fig-0016" title="">Analysis 1.13</a>). </p> <p><a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a> provided data measuring movement disorder average change scores on three different scales (<a href="./references#CD003082-fig-0017" title="">Analysis 1.14</a>). No difference was found on the AIMS scale (1 RCT n = 231), whereas placebo was favoured on the BAS (1 RCT n = 231, MD 0.31 CI 0.10 to 0.52) and SAS (n = 231, MD 1.48 CI 0.76 to 2.20) scales. </p> </section> <section id="CD003082-sec-0139"> <h6 class="title">1.5.2 Other central nervous system (CNS) effects</h6> <p><a href="./references#CD003082-bbs2-0021" title="SelmanFB , McClureRF , HelwigH . Loxapine succinate: A double‐blind comparison with haloperidol and placebo in acute schizophrenics. Current Therapeutic Research1976;19:645‐52. SelmanFB , McClureRF , HelwigH . Loxapine succinate: essai comparatif en double aveugle avec l'haloperidol et un placebo dans les psychoses aigues. Psychololgie Medicale1979;11:1533‐40. ">Selman 1976</a> and <a href="./references#CD003082-bbs2-0012" title="AnutoshS , AliMW , IngenitoG , CarsonWH . Controlled study of aripiprazole and haloperidol in schizophrenia. 11th Association of European Psychiatrists Congress. May 4‐8, Stockholm, Sweden. 2002. CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 13th Congress of the European College of Neuropsychopharmacology [CD‐ROM]: Conifer Excerpta Medica Medical Communications BV. P2075. 2000. DanielD , StockE , WilberC , MarcusR , CarsonWHJr , ManosG , et al. Intramuscular Aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association. May 1‐6; New York, USA. 2004. KaneJM , CarsonWH , SahaAR , McQuadeRD , IngenitoGG , ZimbroffDL , et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry2002;63(9):763‐71. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychoitc disorders: comparison with haloperidol and placebo. 153rd Annual Meeting of the American Psychiatric Association. May 13‐8; Chicago, USA. 2000. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 155th Annual Meeting of the American Psychiatric Association. May 18‐23; Philadelphia, PA, USA. 2002. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Abstracts of the XII CINP Congress, Brussels, Belgium, July 9‐13. 2000. ">Kane 2002</a> found haloperidol appeared more likely to produce blurred vision than placebo (2 RCTs, n = 240, RR 3.96 CI 1.21 to 12.93). <a href="./references#CD003082-bbs2-0021" title="SelmanFB , McClureRF , HelwigH . Loxapine succinate: A double‐blind comparison with haloperidol and placebo in acute schizophrenics. Current Therapeutic Research1976;19:645‐52. SelmanFB , McClureRF , HelwigH . Loxapine succinate: essai comparatif en double aveugle avec l'haloperidol et un placebo dans les psychoses aigues. Psychololgie Medicale1979;11:1533‐40. ">Selman 1976</a> (n = 33) found no clear differences between haloperidol and placebo for confusion or dry mouth. <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a> found no difference between groups for sedation (n = 238; see <a href="./references#CD003082-fig-0018" title="">Analysis 1.15</a>). </p> </section> <section id="CD003082-sec-0140"> <h6 class="title">1.5.3 Cardiovascular effects</h6> <p>Three studies were unable to demonstrate clear differences between groups for incidences of low blood pressure (3 RCTs, n = 245), and <a href="./references#CD003082-bbs2-0004" title="BorisonRL , SinahD , HaverstockS , McLarnonMC , DiamondB . Efficacy and safety of tiospirone vs haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989;25:190‐3. ">Borison 1989</a> also found no effect for raised blood pressure (1 RCT n = 16). Similarly, <a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a> (n = 124) found no difference between haloperidol and placebo for bradycardia (See <a href="./references#CD003082-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD003082-sec-0141"> <h6 class="title">1.5.4 Other adverse effects</h6> <p>Seven studies found haloperidol more likely to induce sleepiness than placebo (7 RCTs, n = 686, RR 3.09 CI 1.51 to 6.31). <a href="./references#CD003082-bbs2-0012" title="AnutoshS , AliMW , IngenitoG , CarsonWH . Controlled study of aripiprazole and haloperidol in schizophrenia. 11th Association of European Psychiatrists Congress. May 4‐8, Stockholm, Sweden. 2002. CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 13th Congress of the European College of Neuropsychopharmacology [CD‐ROM]: Conifer Excerpta Medica Medical Communications BV. P2075. 2000. DanielD , StockE , WilberC , MarcusR , CarsonWHJr , ManosG , et al. Intramuscular Aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association. May 1‐6; New York, USA. 2004. KaneJM , CarsonWH , SahaAR , McQuadeRD , IngenitoGG , ZimbroffDL , et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry2002;63(9):763‐71. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychoitc disorders: comparison with haloperidol and placebo. 153rd Annual Meeting of the American Psychiatric Association. May 13‐8; Chicago, USA. 2000. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 155th Annual Meeting of the American Psychiatric Association. May 18‐23; Philadelphia, PA, USA. 2002. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Abstracts of the XII CINP Congress, Brussels, Belgium, July 9‐13. 2000. ">Kane 2002</a> and <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a> found haloperidol more likely to cause weight gain (2 RCTs, n = 441, RR 4.89 CI 1.41 to 16.95). </p> <p>No significant differences between haloperidol and placebo groups were found for the following adverse effects: agitation (2 RCTs n = 362), anxiety (2 RCTs n = 362), drooling (3 RCTs n = 207), facial oedema (1 RCT n = 33), headache (4 RCTs n = 593), infection (1 RCT n = 24), insomnia (4 RCTs n = 629), nausea/vomiting (2 RCTs n = 231), oral hypoaesthesia (1 RCT n = 238), perspiration (2 RCTs n = 93), or weight loss (3 RCTs n = 385). (See <a href="./references#CD003082-fig-0020" title="">Analysis 1.17</a>). </p> </section> </section> <section id="CD003082-sec-0142"> <h5 class="title">1.6 Economic outcomes</h5> <p>None of the 25 included studies reported on economic outcomes such as cost of care.</p> </section> </section> <section id="CD003082-sec-0143"> <h4 class="title">2. Subgroup analyses</h4> <section id="CD003082-sec-0144"> <h5 class="title">2.1 Gender: men versus women</h5> <p>Most studies included both men and women but did not report results separated by gender. The only primary outcome where results are available for comparison is 'Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks' (<a href="./references#CD003082-fig-0021" title="">Analysis 1.18</a>). <a href="./references#CD003082-bbs2-0010" title="HowardJ . Haloperidol for chronically hospitalised psychotics: A double‐blind comparison with thiothixene and placebo; a follow‐up open evaluation. Diseases of the Nervous System1974;35:458‐63. ">Howard 1974</a> and <a href="./references#CD003082-bbs2-0025" title="VichaiyaV . Clinical trial of haloperidol in schizophrenia. Journal of Psychiatric Association of Thailand1971;16(1):31‐43. ">Vichaiya 1971</a> included only women, whereas, <a href="./references#CD003082-bbs2-0023" title="SimpsonGM , AngusJWS , EdwardsJG . A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research1967;9:407‐12. ">Simpson 1967</a> only men. Results were equally significant for both subgroups (P = 0.20). </p> </section> <section id="CD003082-sec-0145"> <h5 class="title">2.2 Age: adult (18‐65 years) versus child (&lt; 18 years)</h5> <p>All studies, except <a href="./references#CD003082-bbs2-0024" title="SpencerE , AlpertM , PougetE . Scales for the assessment of neuroleptic response in schizophrenic children: Specific measures derived from the CPRS. Psychopharmacology Bulletin1994;30:199‐202. SpencerEK , AlpertM , PougetER . [Two sensitive and specific scales derived from the CPRS for assessing haloperidol response in hospitalised schizophrenic children]. Proceedings of 33rd Annual Meeting of the New Clinical Drug Evaluation Unit. June 1‐4th; Boca Raton, USA. 1993. SpencerEK , KafantarisV , Padron‐GayolMV , RosenbergCR , CampbellM . Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacology Bulletin1992;28:183‐6. ">Spencer 1992</a>, which included only children, included adult participants. For 'Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks' (<a href="./references#CD003082-fig-0022" title="">Analysis 1.19</a>) there were no differences between subgroups (P = 0.07). </p> </section> <section id="CD003082-sec-0146"> <h5 class="title">2.3 Phase of illness: acute versus chronic</h5> <p>Again, only 'Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks' had sufficient data for a comparison to be made among the primary outcomes (<a href="./references#CD003082-fig-0023" title="">Analysis 1.20</a>). There were no differences between subgroups (P = 0.58). </p> </section> <section id="CD003082-sec-0147"> <h5 class="title">2.4 Dose: low dose (≤ 5 mg/day) versus medium to high dose (&gt; 5 mg/day), or as defined by each study </h5> <p>Heterogeneity (I<sup>2</sup> = 72%) was observed for 'Global state: Overall improvement: No marked global improvement, up to six weeks' (<a href="./references#CD003082-fig-0004" title="">Analysis 1.1</a>). When splitting the studies by dose, the heterogeneity was removed, and results from low dose <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a> show no statistically significant difference between haloperidol and placebo, whereas medium to high dose <a href="./references#CD003082-bbs2-0003" title="BechelliLPC , Ruffino‐NettoA , HetemG . A double‐blind controlled trial of pipotiazine, haloperidol and placebo in recently hospitalised acute schizophrenic patients. Brazilian Journal of Biological Research1983;16:305‐11. ">Bechelli 1983</a>, <a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a> and <a href="./references#CD003082-bbs2-0021" title="SelmanFB , McClureRF , HelwigH . Loxapine succinate: A double‐blind comparison with haloperidol and placebo in acute schizophrenics. Current Therapeutic Research1976;19:645‐52. SelmanFB , McClureRF , HelwigH . Loxapine succinate: essai comparatif en double aveugle avec l'haloperidol et un placebo dans les psychoses aigues. Psychololgie Medicale1979;11:1533‐40. ">Selman 1976</a> favour haloperidol (P = 0.003; <a href="./references#CD003082-fig-0024" title="">Analysis 1.21</a>). For 'Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks' results were equally significant for both subgroups (P = 1.00). </p> </section> <section id="CD003082-sec-0148"> <h5 class="title">2.5 Anti‐Parkinson drugs: administration of any anti‐Parkinson drug (any dose) versus administration of haloperidol alone. </h5> <p>We could not perform this subgroup analysis as data for primary outcomes were only available from studies where anti‐Parkinson medication was allowed. </p> </section> <section id="CD003082-sec-0149"> <h5 class="title">2.6 Diagnosis of schizophrenia: operational criteria versus non‐operational diagnoses</h5> <p>The heterogeneity of 'Global state: Overall improvement: No marked global improvement, up to six weeks' (<a href="./references#CD003082-fig-0004" title="">Analysis 1.1</a>) does not diminish or disappear with this subgroup analysis (<a href="./references#CD003082-fig-0025" title="">Analysis 1.22</a>), and no differences between subgroups were observed (P = 0.90). Similarly, there were no differences between subgroups for 'Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks' (P = 0.07) or for 'Global state: Relapse' (P = 0.59). </p> </section> </section> <section id="CD003082-sec-0150"> <h4 class="title">3. Sensitivity analyses</h4> <section id="CD003082-sec-0151"> <h5 class="title">3.1 Implications for randomisation</h5> <p>All included studies either described the method of randomisation or stated that the study was randomised. Had there been studies implying randomisation without stating or describing, we would have performed this sensitivity analysis. </p> </section> <section id="CD003082-sec-0152"> <h5 class="title">3.2 Assumptions for lost binary data</h5> <p>For 'Global state: Overall improvement: No marked global improvement, up to 6 weeks' one study (<a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a>) used LOCF assumptions about missing data. When this study was removed from the analysis the results remained significant (<a href="./references#CD003082-fig-0026" title="">Analysis 1.23</a>), and heterogeneity from the pooled analysis (<a href="./references#CD003082-fig-0004" title="">Analysis 1.1</a>) remains. </p> </section> <section id="CD003082-sec-0153"> <h5 class="title">3.2 Risk of bias</h5> <p>No studies were judged to be at high risk of bias across one or more of the domains of randomisation and therefore no sensitivity analysis was undertaken. </p> </section> <section id="CD003082-sec-0154"> <h5 class="title">3.4 Imputed values</h5> <p>Had we included any cluster‐randomised trials, we would have undertaken a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster‐randomised trials. </p> </section> <section id="CD003082-sec-0155"> <h5 class="title">3.5 On dishonest researchers</h5> <p>It has come to our attention that Dr Richard Borison and Dr Bruce Diamond have been convicted of theft, making false statements and violations of state racketeering law in the USA. At this point, it seems that crimes were to do with criminal diversion of funds, rather than falsifying study data (<a href="http://www.the-scientist.com/?articles.view/articleNo/19152/title/Notebook/" target="_blank">http://www.the‐scientist.com/?articles.view/articleNo/19152/title/Notebook/</a>). Nevertheless, we temporarily removed studies with either of these authors from the analyses to see if this made a substantive difference to the findings. <a href="./references#CD003082-bbs2-0001" title="ArvanitisLA , MillerBG . (ICI 204,636): An atypical antipsychotic: Results from a multiple fixed dose, placebo‐controlled study. Proceedings of XXth Collegium Internationale Neuro‐Psychopharmacologicum. June 23‐27th; Melbourne, Australia. 1996. ArvanitisLA , MillerBG . Quetiapine, an atypical antipsychotic ‐ results from a multiple fixed dose, placebo‐controlled study. Proceedings of 149th Annual Meeting American Psychiatric Association. May 4‐9th. 1996. ArvanitisLA , MillerBG , KowalcykBB . Efficacy of 'Seroquel' (Quetiapine Fumarate) in affective symptoms of schizophrenia). Proceedings of 36th Annual Meeting of the American College of Neuropsychopharmacology. December 8‐12th; Waikoloa, Hawai, USA. 1997. ArvanitisLA , MillerBG , Seroquel Trial 13 Study Group. Multiple fixed doses of &quot;Seroquel&quot; (Quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biological Psychiatry1997;42:233‐46. BorisonRL , ArvanitisLA , MillerBG . A comparison of five fixed doese of 'Seroquel' (ICI 204,636) with haloperidol and placebo in patients with schizophrenia. Proceedings of 8th Biennial Winter Workshop on Schizophrenia. March 16‐22nd; Crans Montana, Switzerland. 1996. BorisonRL , ArvantisLA , MillerBG . A multiple fixed‐dose, placebo‐controlled trial with 'Seroquel' ‐ An atypical antipsychotic. Biological Psychiatry1996;39:333. CantillonM . [Quetiapine fumarate reduces aggression]. Proceedings of the 11th Annual Meeting of the American Association of Geriatric Psychiatry; San Diego, California, USA. 1997. CantillonM , ArvanitisLA , MillerBG , Kowalcyk . 'Seroquel' (Quetiapine Fumarate) reduces hostility and aggression in patients with acute schizophrenia. Proceedings of 36th Annual Meeting of the American College of Neuropsychopharmacology. December 8‐12th; Waikoloa, Hawai, USA. 1997. CantillonM , GoldsteinJM . Efficacy of Quetiapine fumarate in affective symptoms of schizophrenia. Proceedings of American Psychiatric Association Annual Meeting. May 30th‐June 4th; Toronto, Ontario, Canada. 1998. HellewellJSE , Cameron‐HandsD , CantillonM . Seroquel: Evidence for efficacy in the treatment of hostility and aggression. 9th Biennial Winter Workshop on Schizophrenia. February 7‐13th; Davos, Switzerland. 1998. HongW , ArvanitisL . Reduction of the positive symptoms of schizophrenia by (ICI 204,636): Results from phase II and III clinical trials. Proceedings of 9th European College of Neuropsychopharmacology Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. HongWW , ArvanitisL . The atypical profile of (ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic patients. Proceedings of the 9th European College of Neuropsychopharmacology Congress. September 21‐25th; Amsterdam, The Netherlands. 1996. HongWW , ArvanitisLA , MillerBG . (ICI 204,636) does not differ from placebo in the incidence of EPS or effect on plasma prolactin. Proceedings of the XXth Collegium Internationale Neuro‐psychopharmacologicum. June 23‐27th; Melbourne, Australia. 1996. HongWW , ArvanitisLA , MillerBG . Quetiapine does not differ from placebo in the incidence of extrapyramidal syndrome of effect on plasma prolactin. Proceedings of the 149th Annual Meeting American Psychiatric Association. May 4‐9th. 1996. ">Arvanitis 1997</a> only provided data for leaving the study early. <a href="./references#CD003082-bbs2-0004" title="BorisonRL , SinahD , HaverstockS , McLarnonMC , DiamondB . Efficacy and safety of tiospirone vs haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989;25:190‐3. ">Borison 1989</a> and <a href="./references#CD003082-bbs2-0005" title="BorisonR , PathiragaA , DiamondB , MeibachR . Risperidone and Schizophrenia. Proceedings of 5th World Congress of Biological Psychiatry. June 9‐14th; Florence, Italy. 1991. BorisonRL , DiamondBI , AugustaGA . Serotonin modulation of dopaminergic‐medicated extrapyramidal side effects. Proceedings of 43rd Annual Meeting of the American Academy of Neurology. April 21‐27th; Boston, USA. 1991. BorisonRL , DiamondBI , PathirajaA , MeibachRC . Clinical profile of risperidone in chronic schizophrenia. Proceedings of 17th Congress of Collegium Internationale Neuro‐psychopharmacologicum. 1993. BorisonRL , PathirajaAP , DiamondB , MeibachRC . Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin1992;28:213‐8. ">Borison 1992a</a> also reported on this outcome but also presented usable data on mental state (&lt; 20% reduction in BPRS), and a range of adverse effects. In every case, where data from these trials are added to those of others, removal of the studies never resulted in substantive changes in the findings. For example, most data are available for the outcome of leaving the study early. With all trials included, the results favour the haloperidol group (16 RCTs n = 1812, RR 0.87 CI 0.80 to 0.95; <a href="./references#CD003082-fig-0008" title="">Analysis 1.5</a>). Removing the three studies results in no change. Where difficulties arise is where <a href="./references#CD003082-bbs2-0004" title="BorisonRL , SinahD , HaverstockS , McLarnonMC , DiamondB . Efficacy and safety of tiospirone vs haloperidol and thioridazine in a double‐blind, placebo‐controlled trial. Psychopharmacology Bulletin1989;25:190‐3. ">Borison 1989</a> or <a href="./references#CD003082-bbs2-0005" title="BorisonR , PathiragaA , DiamondB , MeibachR . Risperidone and Schizophrenia. Proceedings of 5th World Congress of Biological Psychiatry. June 9‐14th; Florence, Italy. 1991. BorisonRL , DiamondBI , AugustaGA . Serotonin modulation of dopaminergic‐medicated extrapyramidal side effects. Proceedings of 43rd Annual Meeting of the American Academy of Neurology. April 21‐27th; Boston, USA. 1991. BorisonRL , DiamondBI , PathirajaA , MeibachRC . Clinical profile of risperidone in chronic schizophrenia. Proceedings of 17th Congress of Collegium Internationale Neuro‐psychopharmacologicum. 1993. BorisonRL , PathirajaAP , DiamondB , MeibachRC . Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin1992;28:213‐8. ">Borison 1992a</a> report unique outcomes. In these cases, of course, removal of the study results in the deletion of the complete outcome. This applies to the outcome of &lt; 20% reduction in BPRS (<a href="./references#CD003082-fig-0009" title="">Analysis 1.6</a>), and the adverse effects of high blood pressure (<a href="./references#CD003082-fig-0019" title="">Analysis 1.16</a>) and infection (<a href="./references#CD003082-fig-0020" title="">Analysis 1.17</a>) (see <a href="#CD003082-sec-0170">Potential biases in the review process</a>). </p> </section> </section> <section id="CD003082-sec-0156"> <h4 class="title">4. Reporting biases (publication bias)</h4> <p>Only one outcome in this review lent itself to producing a funnel plot, i.e. had more than 10 included studies; 'Global state: Leaving the study early, up to six weeks'. The funnel plot was symmetrical for this outcome. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003082-sec-0157" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003082-sec-0157"></div> <section id="CD003082-sec-0158"> <h3 class="title" id="CD003082-sec-0158">Summary of main results</h3> <p>Twenty‐five trials enrolling 4651 participants met the inclusion criteria. The summary below reflects the outcomes chosen for <a href="./full#CD003082-tbl-0001">summary of findings Table for the main comparison</a>, and considered the main findings of this review that can support evidence‐based decision making. </p> <section id="CD003082-sec-0159"> <h4 class="title">1. Overall global improvement</h4> <p>Moderate quality evidence indicates that the efficacy of haloperidol for improving global state is 33% for both up to six weeks follow‐up and for six weeks to six months follow‐up. In the clinical environment haloperidol is clearly a valuable antipsychotic. However, there were no studies that reported on this outcome beyond six months. </p> </section> <section id="CD003082-sec-0160"> <h4 class="title">2. Hospital discharge</h4> <p>Only one, small study (<a href="./references#CD003082-bbs2-0010" title="HowardJ . Haloperidol for chronically hospitalised psychotics: A double‐blind comparison with thiothixene and placebo; a follow‐up open evaluation. Diseases of the Nervous System1974;35:458‐63. ">Howard 1974</a>), reported on discharge from hospital and no significant differences were observed. </p> </section> <section id="CD003082-sec-0161"> <h4 class="title">3. Relapse</h4> <p>Results from two small studies (<a href="./references#CD003082-bbs2-0018" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics. Psychopharmacology1982;77:301‐4. ">Nishikawa 1982</a> and <a href="./references#CD003082-bbs2-0019" title="NishikawaT , TsudaA , TanakaM , HoakiY , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics: A comparative dose‐response study of haloperidol and propericiazine. Psychopharmacology1984;82:153‐6. ">Nishikawa 1984</a>) show that haloperidol reduced the number of participants experiencing a relapse by 31% from six months to one year follow‐up. Based solely on this very low quality evidence, we cannot say whether haloperidol prevents relapses in real, clinical settings. </p> </section> <section id="CD003082-sec-0162"> <h4 class="title">4. Leaving the study early</h4> <p>Just less than half those allocated haloperidol and just over half of those given placebo did not complete the six‐week studies. Although the result does favour haloperidol, this is a shocking loss of data and much greater than is seen in the companion review, 'Chlorpromazine versus placebo for schizophrenia' (<a href="./references#CD003082-bbs2-0135" title="Adams CE , AwadG , RathboneJ , ThornleyB . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD000284.pub2] ">Adams 2007</a>). There is no suggestion that this attrition, much greater than would be expected in normal clinical practice, has changed over three decades of trials. Clearly the trial design is either unacceptable to participants or is asking researchers to withdraw participants for reasons that are not apparent to those reading the final reports. In any event this is not acceptable. </p> </section> <section id="CD003082-sec-0163"> <h4 class="title">5. Mental state</h4> <p>We expected more data on the specific symptoms of schizophrenia. One set of mental state data were presented in a study undertaken by dishonest researchers (<a href="./references#CD003082-bbs2-0005" title="BorisonR , PathiragaA , DiamondB , MeibachR . Risperidone and Schizophrenia. Proceedings of 5th World Congress of Biological Psychiatry. June 9‐14th; Florence, Italy. 1991. BorisonRL , DiamondBI , AugustaGA . Serotonin modulation of dopaminergic‐medicated extrapyramidal side effects. Proceedings of 43rd Annual Meeting of the American Academy of Neurology. April 21‐27th; Boston, USA. 1991. BorisonRL , DiamondBI , PathirajaA , MeibachRC . Clinical profile of risperidone in chronic schizophrenia. Proceedings of 17th Congress of Collegium Internationale Neuro‐psychopharmacologicum. 1993. BorisonRL , PathirajaAP , DiamondB , MeibachRC . Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin1992;28:213‐8. ">Borison 1992a</a>), where no differences were observed between haloperidol and placebo. Results from change data on the BPRS scale from <a href="./references#CD003082-bbs2-0014" title="KlieserE , LehmannE . Experimental examination of trazodone. Clinical Neuropharmacology1989;12:S18‐24. ">Klieser 1989</a> also showed no differences. On the other hand, <a href="./references#CD003082-bbs2-0003" title="BechelliLPC , Ruffino‐NettoA , HetemG . A double‐blind controlled trial of pipotiazine, haloperidol and placebo in recently hospitalised acute schizophrenic patients. Brazilian Journal of Biological Research1983;16:305‐11. ">Bechelli 1983</a> and <a href="./references#CD003082-bbs2-0011" title="JannMW , CrabtreeBL , PittsWM , Francis LamYW , CarterJG . Plasma alpha‐one acid glycoprotein and haloperidol concentrations in schizophrenic patients. Neuropsychobiology1997;36:32‐6. ">Jann 1997</a> (n = 72) found a significant difference, favouring haloperidol, by approximately 12 points on the BPRS at six weeks. <a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a> (n = 119) and <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a> (n = 234) reported data from the PANSS; they found significant results favouring haloperidol on the total (by 15.6 points), positive (by 3.3 points) and negative (by 1.2 points) subscales. We are unsure whether these are clinically significant findings. </p> </section> <section id="CD003082-sec-0164"> <h4 class="title">6. Adverse effects</h4> <p>Use of haloperidol has long been associated with movement disorders, and trial‐derived data would seem to fit with clinical experience. Evidence from this review indicate that haloperidol causes different extrapyramidal symptoms (EPS) such as akathisia, dystonia, parkinsonism, rigidity and tremor, and more people given haloperidol needed anti‐Parkinson medication than those given placebo. On the other hand, there was no evidence that haloperidol causes other EPS such as oculogyric crises, teeth grinding, or 'thick' speech. There were so few long‐term data that rates of tardive dyskinesia were difficult to quantify with confidence. Although not noted as being a sedating antipsychotic, haloperidol does commonly induce sleepiness. Also, people given haloperidol tend to gain weight. </p> </section> <section id="CD003082-sec-0165"> <h4 class="title">7. Subgroup analyses</h4> <p>The power to detect a real difference between studies in any one of the subgroup analyses was very low. The only statistically significant difference was for low versus medium to high dose for the outcome 'Global state: Overall improvement: No marked global improvement, up to six weeks'. Pooled results for this outcome had high heterogeneity (I<sup>2</sup> = 72%); this heterogeneity disappeared when trials were split into subgroups of low and medium to high dose haloperidol. For low dose (4 mg/day), <a href="./references#CD003082-bbs2-0013" title="KaneJ , ZhaoJ , CohenM , PanagidesJ . Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophrenia Research2008;98:14. KaneJM , CohenM , ZhaoJ , AlphsL , PanagidesJ . Efficacy and safety of asenapine in a placebo‐ and haloperidol‐controlled trial in patients with acute exacerbation of schizophrenia. Journal of Clinical Psychopharmacology2010;30(2):106‐15. ">Kane 2010</a> did not observe any difference in global improvement between haloperidol and placebo, whereas for medium to high doses (&gt; 5 mg/day), <a href="./references#CD003082-bbs2-0003" title="BechelliLPC , Ruffino‐NettoA , HetemG . A double‐blind controlled trial of pipotiazine, haloperidol and placebo in recently hospitalised acute schizophrenic patients. Brazilian Journal of Biological Research1983;16:305‐11. ">Bechelli 1983</a>, <a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a> and <a href="./references#CD003082-bbs2-0021" title="SelmanFB , McClureRF , HelwigH . Loxapine succinate: A double‐blind comparison with haloperidol and placebo in acute schizophrenics. Current Therapeutic Research1976;19:645‐52. SelmanFB , McClureRF , HelwigH . Loxapine succinate: essai comparatif en double aveugle avec l'haloperidol et un placebo dans les psychoses aigues. Psychololgie Medicale1979;11:1533‐40. ">Selman 1976</a> found that haloperidol was 52% more effective than placebo. </p> </section> </section> <section id="CD003082-sec-0166"> <h3 class="title" id="CD003082-sec-0166">Overall completeness and applicability of evidence</h3> <section id="CD003082-sec-0167"> <h4 class="title">Completeness</h4> <p>Given that haloperidol is so widely used in routine practice across the world, and is a common control drug for randomised trials of new compounds, readers may have expected more data; certainly we did. We were especially surprised not to find a single study that reported on deaths. In addition, no study reported on satisfaction with treatment, cost of care or behavioural outcomes. Also, only one study reported on hospitalisation and only two on relapse.  If further data from randomised trials become available, this review will be updated and might report results with greater confidence. Nevertheless, to date, this systematic review represents a rare attempt to quantify the effects of this potent antipsychotic in some clinically meaningful terms. </p> </section> <section id="CD003082-sec-0168"> <h4 class="title">Applicability</h4> <p>The 25 included studies in this review included many people who would be recognisable in everyday practice. There were those with strictly diagnosed illness and those whose illness was diagnosed using less rigorous criteria; the results of the subgroup analyses on diagnostic rigour (see <a href="#CD003082-sec-0122">Effects of interventions</a>, section 2.6) support the assertion that the results are widely applicable. However, most studies were undertaken in hospital, whereas the great majority of people with schizophrenia are in the community, and thus, generalising to treatment in community settings could be problematic. </p> <p>In addition, the dose of haloperidol in 68% of the included studies was high (10‐200 mg/day), see <a href="./references#CD003082-sec-0198" title="">Characteristics of included studies</a>, and one of the subgroup analyses on dose revealed a difference between low‐ and medium‐ to high‐dose haloperidol (see <a href="#CD003082-sec-0122">Effects of interventions</a> section 2.4) suggesting results may not be fully applicable to any haloperidol dose. </p> <p>Finally, most studies were conducted in Europe and North America, therefore, results may not be applicable to Africa, Asia, Australia or South America. </p> </section> </section> <section id="CD003082-sec-0169"> <h3 class="title" id="CD003082-sec-0169">Quality of the evidence</h3> <p>The quality of the evidence is moderate to very low based on GRADE (<a href="./references#CD003082-bbs2-0170" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>). Overall, outcomes with a small number of participants were rated very low quality, and other outcomes moderate quality. None were rated high quality as most studies had an overall unclear to high risk of bias. The great majority of studies did not report the method of randomisation, and only one trial described the method of allocation concealment. Although all studies were reported to be double‐blind, it was not clearly described in most trials. Thirty‐six per cent out of the included studies were rated as high risk of bias for incomplete outcome reporting, mainly due to very high losses to follow‐up. Data presentation was poor, with most scale data rendered unusable (see <a href="./references#CD003082-sec-0198" title="">Characteristics of included studies</a>). Studies failed to report variances, reported only P values, or did not report the result at all. In this way a lot of potentially informative data were lost. Consequently, 68% of the trials were rated as high risk of selective reporting bias. With closer adherence to the CONSORT statement (<a href="./references#CD003082-bbs2-0142" title="BeggC , ChoM , EastwoodS , HortonR , MoherD , OlkinI , et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA1996;276(8):637‐9. ">Begg 1996</a>), data reporting should improve, although it should be noted that some of the most recent trials (<a href="./references#CD003082-bbs2-0008" title="GarciaE , RobertM , PerisF , NakamuraH , SatoN , TerazawaY . The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: a randomized, double‐blind, placebo‐controlled, multicentre study. CNS Drugs2009;23(7):615‐25. [MEDLINE: 19552488] ">Garcia 2009</a> and <a href="./references#CD003082-bbs2-0012" title="AnutoshS , AliMW , IngenitoG , CarsonWH . Controlled study of aripiprazole and haloperidol in schizophrenia. 11th Association of European Psychiatrists Congress. May 4‐8, Stockholm, Sweden. 2002. CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 13th Congress of the European College of Neuropsychopharmacology [CD‐ROM]: Conifer Excerpta Medica Medical Communications BV. P2075. 2000. DanielD , StockE , WilberC , MarcusR , CarsonWHJr , ManosG , et al. Intramuscular Aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association. May 1‐6; New York, USA. 2004. KaneJM , CarsonWH , SahaAR , McQuadeRD , IngenitoGG , ZimbroffDL , et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry2002;63(9):763‐71. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychoitc disorders: comparison with haloperidol and placebo. 153rd Annual Meeting of the American Psychiatric Association. May 13‐8; Chicago, USA. 2000. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 155th Annual Meeting of the American Psychiatric Association. May 18‐23; Philadelphia, PA, USA. 2002. KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Abstracts of the XII CINP Congress, Brussels, Belgium, July 9‐13. 2000. ">Kane 2002</a>) still failed to present standard deviations for some or all of their continuous data. </p> </section> <section id="CD003082-sec-0170"> <h3 class="title" id="CD003082-sec-0170">Potential biases in the review process</h3> <section id="CD003082-sec-0171"> <h4 class="title">1. Failing to identify old trials</h4> <p>We identified trials by meticulous searching, including Janssen‐Cilag UK helping the original search. Despite this, it is reasonable to assume that no data set is complete for haloperidol, one of the oldest antipsychotic drugs. Nevertheless, we do not feel that we have omitted very many highly influential studies. </p> </section> <section id="CD003082-sec-0172"> <h4 class="title">2. Under‐reporting of trial methodology</h4> <p>As can be seen in <a href="#CD003082-fig-0002">Figure 2</a>, most trials were rated unclear risk of bias for randomisation generation, allocation concealment and blinding. This was because the trial reports did not specify the methods adequately. Consequently, we downgraded the quality of the evidence in the <a href="./full#CD003082-tbl-0001">summary of findings Table for the main comparison</a>, and by doing so we may have introduced bias. </p> </section> <section id="CD003082-sec-0173"> <h4 class="title">3. Sensitivity analyses on dishonest researchers</h4> <p>We felt that it would be harsh to immediately delete all trial data associated with Drs Borison and Diamond without empirical data. That removal of their data makes no discernable difference to any outcome is reassuring. </p> </section> </section> <section id="CD003082-sec-0174"> <h3 class="title" id="CD003082-sec-0174">Agreements and disagreements with other studies or reviews</h3> <p>We know of two systematic reviews of randomised controlled trials that evaluate haloperidol versus placebo for schizophrenia: i. <a href="./references#CD003082-bbs2-0155" title="Gao K , KempDE , GanocySJ , GajwaniP , XiaG , CalabreseJR . Antipsychotic‐induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. Journal of Clinical Psychopharmacology2008 Apr;28(2):203‐9. ">Gao 2008</a> systematically reviewed extrapyramidal side effects and, similar to our results, found that there was a higher risk of developing akathisia and overall EPS with haloperidol compared with placebo; ii. <a href="./references#CD003082-bbs2-0163" title="Klemp M ,  TveteIF ,  SkomedalT ,  GaasemyrJ ,  NatvigB ,  AursnesI . A review and Bayesian meta‐analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. Journal of Clinical Psychopharmacology2011 Dec;31(6):698‐704. ">Klemp 2011</a> reviewed the clinical efficacy and adverse effects of four atypical antipsychotics compared with haloperidol and placebo, and in agreement with our results found that haloperidol had a significantly better antipsychotic effect than placebo, and that haloperidol induces weight gain and EPS compared with placebo. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003082-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003082-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/full#CD003082-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003082-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/full#CD003082-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003082-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/full#CD003082-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 1 Global state: 1a. Overall improvement: No marked global improvement." data-id="CD003082-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 1 Global state: 1a. Overall improvement: No marked global improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 2 Global state: 1b. Overall improvement: Average change in CGI‐S score (up to 6 weeks; high = poor)." data-id="CD003082-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 2 Global state: 1b. Overall improvement: Average change in CGI‐S score (up to 6 weeks; high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 3 Global state: 2. Hospital discharge: Not discharged from hospital (&gt; 6‐24 weeks)." data-id="CD003082-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 3 Global state: 2. Hospital discharge: Not discharged from hospital (&gt; 6‐24 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 4 Global state: 3. Relapse (&lt; 52 weeks)." data-id="CD003082-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 4 Global state: 3. Relapse (&lt; 52 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 5 Global state: 4. Leaving the study early." data-id="CD003082-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 5 Global state: 4. Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 6 Mental state: 1. No clinical improvement (&lt; 20% reduction in BPRS score; up to 6 weeks)." data-id="CD003082-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 6 Mental state: 1. No clinical improvement (&lt; 20% reduction in BPRS score; up to 6 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 7 Mental state: 2a. General symptoms: Average BPRS total score (up to 6 weeks; high = poor)." data-id="CD003082-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 7 Mental state: 2a. General symptoms: Average BPRS total score (up to 6 weeks; high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 8 Mental state: 2b. General symptoms: Average change in PANSS total score (up to 6 weeks; high = poor)." data-id="CD003082-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 8 Mental state: 2b. General symptoms: Average change in PANSS total score (up to 6 weeks; high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 9 Mental state: 3. Positive symptoms: Average change in PANSS positive score (up to 6 weeks; high = poor)." data-id="CD003082-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 9 Mental state: 3. Positive symptoms: Average change in PANSS positive score (up to 6 weeks; high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 10 Mental state: 4. Negative symptoms: Average change in PANSS negative score (up to 6 weeks; high = poor)." data-id="CD003082-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 10 Mental state: 4. Negative symptoms: Average change in PANSS negative score (up to 6 weeks; high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 11 Mental state: 5. Mood: Average change in CDS score (up to 6 weeks; high = poor)." data-id="CD003082-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 11 Mental state: 5. Mood: Average change in CDS score (up to 6 weeks; high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 12 Adverse effects: 1a. Movement disorders: Extrapyramidal symptoms." data-id="CD003082-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 12 Adverse effects: 1a. Movement disorders: Extrapyramidal symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 13 Adverse effects: 1b. Movement disorders: Tardive dyskinesia." data-id="CD003082-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 13 Adverse effects: 1b. Movement disorders: Tardive dyskinesia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 14 Adverse effects: 1c. Movement disorders: Average changes scores (various scales; up to 6 weeks)." data-id="CD003082-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 14 Adverse effects: 1c. Movement disorders: Average changes scores (various scales; up to 6 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 15 Adverse effects: 2. Other CNS." data-id="CD003082-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 15 Adverse effects: 2. Other CNS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 16 Adverse effects: 3. Cardiovascular effects." data-id="CD003082-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 16 Adverse effects: 3. Cardiovascular effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 17 Adverse effects: 4. Other adverse effects." data-id="CD003082-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 17 Adverse effects: 4. Other adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 18 SUBGROUP ANALYSIS: 1. MEN vs WOMEN: Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks (clinician rated)." data-id="CD003082-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 18 SUBGROUP ANALYSIS: 1. MEN vs WOMEN: Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks (clinician rated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 19 SUBGROUP ANALYSIS: 2. 18‐65 YEARS vs &lt; 18 YEARS: Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks (clinician rated)." data-id="CD003082-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 19 SUBGROUP ANALYSIS: 2. 18‐65 YEARS vs &lt; 18 YEARS: Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks (clinician rated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 20 SUBGROUP ANALYSIS: 3. ACUTE vs CHRONIC: Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks (clinician rated)." data-id="CD003082-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 20 SUBGROUP ANALYSIS: 3. ACUTE vs CHRONIC: Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks (clinician rated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 21 SUBGROUP ANALYSIS: 4. LOW DOSE vs MEDIUM TO HIGH DOSE." data-id="CD003082-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 21 SUBGROUP ANALYSIS: 4. LOW DOSE vs MEDIUM TO HIGH DOSE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 22 SUBGROUP ANALYSIS: 5. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA." data-id="CD003082-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 22 SUBGROUP ANALYSIS: 5. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003082-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/urn:x-wiley:14651858:media:CD003082:CD003082-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_t/tCD003082-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 23 SENSITIVITY ANALYSIS: 1. ASSUMPTIONS FOR MISSING DATA vs NO ASSUMPTIONS FOR MISSING DATA: Global state: Overall improvement: No marked global improvement, up to 6 weeks (clinician rated)." data-id="CD003082-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 HALOPERIDOL versus PLACEBO, Outcome 23 SENSITIVITY ANALYSIS: 1. ASSUMPTIONS FOR MISSING DATA vs NO ASSUMPTIONS FOR MISSING DATA: Global state: Overall improvement: No marked global improvement, up to 6 weeks (clinician rated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/media/CDSR/CD003082/image_n/nCD003082-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003082-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HALOPERIDOL versus PLACEBO for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>HALOPERIDOL versus PLACEBO for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> hospital and community<br/> <b>Intervention:</b> HALOPERIDOL versus PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HALOPERIDOL versus PLACEBO</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death ‐ suicide and natural causes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall improvement: No marked global improvement</b> <br/> Rated by clinician<br/> Follow‐up: &gt;6‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>841 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>564 per 1000</b> <br/> (488 to 656) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.67</b> <br/> (0.58 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>307<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Another four trials reported on this outcome at up to six weeks follow‐up, and one trial at &gt; 6‐24 weeks follow‐up using a nurse‐rated scale, both sub‐analyses showed significant results in favour of haloperidol. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Not discharged from hospital</b> <br/> Follow‐up: &gt; 6‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>625 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>531 per 1000</b> <br/> (294 to 950) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> <br/> (0.47 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> <br/> Follow‐up: &lt; 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>690 per 1000</b> <br/> (550 to 860) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b> <br/> (0.55 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: &gt; 6‐24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>134 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> <br/> (39 to 134) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.54</b> <br/> (0.29 to 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Another 16 trials reported on this outcome at up to six weeks follow‐up showing a significant result in favour of haloperidol. One trial at &lt; 52 weeks follow‐up showed no difference between haloperidol and placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: Movement disorders ‐ parkinsonism</b> <br/> Follow‐up: 3 weeks to 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>154 per 1000</b> <br/> (75 to 315) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.48</b> <br/> (2.68 to 11.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Several studies also reported on other, specific movement disorders: there was a significant result favouring placebo for akathisia, dystonia, needing anti‐Parkinson medication, rigidity and tremor; there was no difference between haloperidol and placebo for tardive dyskinesia, oculogyric crises, teeth grinding and 'thick' speech. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Seven out of the eight included studies had an unclear risk of bias for random sequence generation and for allocation concealment. Blinding of participants and personnel was unclear in four studies and blinding of assessors was unclear in six. Two studies had an unclear risk of bias for incomplete outcome data. One study had a high risk of other bias as they were funded by industry and three an unclear risk of bias as the drugs were provided by a pharmaceutical company.<br/> <sup>2</sup> The included study had an unclear risk of bias for random sequence generation, allocation concealment, and blinding of outcome assessors.<br/> <sup>3</sup> The total number of participants and events were very low.<br/> <sup>4</sup> Only one out of the 25 included studies reported on this outcome.<br/> <sup>5</sup> The two included studies had an unclear risk of bias for random sequence generation, allocation concealment, and for blinding of outcome assessors. One study had a high risk of bias for incomplete outcome data, the other an unclear risk of bias.<br/> <sup>6</sup> Only two out of the 25 included studies reported on this outcome.<br/> <sup>7</sup> Four out of the five included studies had an unclear risk of bias for random sequence generation, and all five studies had an unclear risk of bias for allocation concealment. Blinding of participants and personnel was unclear in two studies and blinding of assessors was unclear in four. One study had a high risk of bias for incomplete outcome data, and two for other bias as they were funded by industry or the drugs were provided by a pharmaceutical company. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HALOPERIDOL versus PLACEBO for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/full#CD003082-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003082-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">HALOPERIDOL versus PLACEBO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1a. Overall improvement: No marked global improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 up to 6 weeks (clinician rated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.56, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 &gt; 6‐24 weeks (clinician rated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.58, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 &gt; 6‐24 weeks (nurse rated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.37, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 1b. Overall improvement: Average change in CGI‐S score (up to 6 weeks; high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.73, ‐0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 2. Hospital discharge: Not discharged from hospital (&gt; 6‐24 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.47, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 3. Relapse (&lt; 52 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.55, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Global state: 4. Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 up to 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.80, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 &gt; 6‐24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.29, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 &lt; 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [0.14, 46.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 1. No clinical improvement (&lt; 20% reduction in BPRS score; up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.54, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 2a. General symptoms: Average BPRS total score (up to 6 weeks; high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.76 [‐14.60, ‐4.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 2b. General symptoms: Average change in PANSS total score (up to 6 weeks; high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.58 [‐23.92, ‐7.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 3. Positive symptoms: Average change in PANSS positive score (up to 6 weeks; high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.29 [‐4.70, ‐1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 4. Negative symptoms: Average change in PANSS negative score (up to 6 weeks; high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.18 [‐2.32, ‐0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mental state: 5. Mood: Average change in CDS score (up to 6 weeks; high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.20, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 1a. Movement disorders: Extrapyramidal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.66 [2.24, 5.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.49 [3.23, 40.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 needing antiparkinson medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.23 [2.20, 4.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 oculogyric crises</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.14, 6.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 parkinsonism (including EPS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.48 [2.68, 11.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 rigidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.98 [2.74, 9.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.7 teeth grinding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [0.11, 57.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.8 'thick' speech</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.89 [0.33, 105.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.9 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.93 [1.96, 7.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 1b. Movement disorders: Tardive dyskinesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 dyskinesia and tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.14, 7.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 1c. Movement disorders: Average changes scores (various scales; up to 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 AIMS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.71, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 BAS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.10, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 SAS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.76, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 2. Other CNS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.96 [1.21, 12.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 confusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [0.11, 57.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.62, 4.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.24, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 3. Cardiovascular effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 blood pressure ‐ dizziness/low BP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.36, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 blood pressure ‐ high BP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.14, 64.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.27 [0.49, 37.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 4. Other adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.54, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.33, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 drooling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [0.88, 18.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 facial oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [0.12, 64.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.62, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.6 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.40, 122.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.7 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.76, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.8 nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.49, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.9 oral hypoaesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.10 perspiration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.74 [0.58, 38.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.11 sleepiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [1.51, 6.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.12 weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.89 [1.41, 16.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.13 weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.36, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 SUBGROUP ANALYSIS: 1. MEN vs WOMEN: Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks (clinician rated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 only men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.27, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 only women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.55, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 SUBGROUP ANALYSIS: 2. 18‐65 YEARS vs &lt; 18 YEARS: Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks (clinician rated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 18‐65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.61, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 &lt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.10, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 SUBGROUP ANALYSIS: 3. ACUTE vs CHRONIC: Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks (clinician rated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 acute phase of illness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.30, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 chronic phase of illness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.59, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 SUBGROUP ANALYSIS: 4. LOW DOSE vs MEDIUM TO HIGH DOSE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 low dose (≤ 5 mg/day) ‐ Global state: Overall improvement: No marked global improvement, up to 6 weeks (clinician rated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.69, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 medium to high dose (&gt; 5 mg/day) ‐ Global state: Overall improvement: No marked global improvement, up to 6 weeks (clinician rated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.35, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 low dose (≤ 5 mg/day) ‐ Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks (clinician rated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.55, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4 medium to high dose (&gt; 5 mg/day) ‐ Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks (clinician rated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.54, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 SUBGROUP ANALYSIS: 5. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 operational criteria used for diagnosis ‐ Global state: Overall improvement: No marked global improvement, up to 6 weeks (clinician rated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.56, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 no operational criteria used for diagnosis ‐ Global state: Overall improvement: No marked global improvement, up to 6 weeks (clinician rated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.33, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 operational criteria used for diagnosis ‐ Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks (clinician rated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.10, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.4 no operational criteria used for diagnosis ‐ Global state: Overall improvement: No marked global improvement, &gt; 6‐24 weeks (clinician rated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.61, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5 operational criteria used for diagnosis ‐ Global state: Relapse (&lt; 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.57, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.6 no operational criteria used for diagnosis ‐ Global state: Relapse (&lt; 52 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.37, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 SENSITIVITY ANALYSIS: 1. ASSUMPTIONS FOR MISSING DATA vs NO ASSUMPTIONS FOR MISSING DATA: Global state: Overall improvement: No marked global improvement, up to 6 weeks (clinician rated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 no assumptions for missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.60, 0.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">HALOPERIDOL versus PLACEBO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003082.pub3/references#CD003082-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003082.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003082-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003082-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003082-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD003082-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD003082-note-0001">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003082\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003082\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003082\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003082\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003082\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6iOnQIUh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003082.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003082.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003082.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003082.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003082.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718365414"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003082.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718365418"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003082.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dce8f381b935f',t:'MTc0MDcxODM2NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 